Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 1074 articles:
HTML format



Single Articles


    July 2021
  1. FUNG AS, Graham DM, Chen EX, Stockley TL, et al
    A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
    Lung Cancer. 2021;157:21-29.
    PubMed     Abstract available


  2. POPAT S, Brustugun OT, Cadranel J, Felip E, et al
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer. 2021;157:9-16.
    PubMed     Abstract available


  3. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
    Lung Cancer. 2021;157:167.
    PubMed    


  4. CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
    Lymph Node Dissection in Thymoma: Is it worth it?
    Lung Cancer. 2021;157:156-162.
    PubMed     Abstract available


  5. XIE XJ, Liu SY, Chen JY, Zhao Y, et al
    Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Lung Cancer. 2021;157:30-39.
    PubMed     Abstract available


  6. TALCOTT WJ, Miccio JA, Park HS, White AA, et al
    Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
    Lung Cancer. 2021;157:17-20.
    PubMed     Abstract available


  7. ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
    Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Lung Cancer. 2021;157:147-155.
    PubMed     Abstract available


  8. LESIRE B, Durieux V, Grigoriu B, Girard N, et al
    Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
    Lung Cancer. 2021;157:131-146.
    PubMed     Abstract available


  9. SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
    High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2021;157:1-8.
    PubMed     Abstract available


  10. YANG Y, Ran J, Wang Y, Zhou Z, et al
    Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
    Lung Cancer. 2021;157:116-123.
    PubMed     Abstract available


  11. PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
    Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
    Lung Cancer. 2021;157:85-91.
    PubMed     Abstract available


  12. BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
    Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
    Lung Cancer. 2021;157:79-84.
    PubMed     Abstract available


  13. CHINTALA NK, Restle D, Quach H, Saini J, et al
    CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
    Lung Cancer. 2021;157:48-59.
    PubMed     Abstract available


  14. CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
    A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
    Lung Cancer. 2021;157:165-166.
    PubMed    


  15. BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
    Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
    Lung Cancer. 2021;157:163-164.
    PubMed    


    June 2021
  16. SU PL, Tsai JS, Yang SC, Wu YL, et al
    Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
    Lung Cancer. 2021;158:137-145.
    PubMed     Abstract available


  17. WANG Z, Zhao J, Ma Z, Cui J, et al
    Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268].
    Lung Cancer. 2021 Jun 11. pii: S0169-5002(21)00426.
    PubMed    


  18. BORG M, Wen SWC, Nederby L, Hansen TF, et al
    Performance of the EarlyCDT(R) Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Lung Cancer. 2021;158:85-90.
    PubMed     Abstract available


  19. QI M, Bian D, Zhang J, Zhu X, et al
    The modification of T description according to visceral pleural invasion and tumor size from 3.1cm to 4.0cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
    Lung Cancer. 2021;158:47-54.
    PubMed     Abstract available


  20. JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
    Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
    Lung Cancer. 2021;156:147-150.
    PubMed     Abstract available


  21. GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
    LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2021;156:129-135.
    PubMed     Abstract available


  22. LAROSE F, Quigley N, Lacasse Y, Martel S, et al
    Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
    Lung Cancer. 2021;156:151-156.
    PubMed     Abstract available


  23. PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
    Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
    Lung Cancer. 2021;156:117-121.
    PubMed     Abstract available


  24. SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
    Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
    Lung Cancer. 2021;156:109-116.
    PubMed     Abstract available


  25. LAU SCM, Poletes C, Le LW, Mackay KM, et al
    Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lung Cancer. 2021;156:76-81.
    PubMed     Abstract available


  26. NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
    A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
    Lung Cancer. 2021;156:1-4.
    PubMed     Abstract available


    May 2021
  27. KIM HW, Kim JS, Lee SH
    Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Lung Cancer. 2021;158:107-114.
    PubMed     Abstract available


  28. SATO T, Shimada Y, Mimae T, Tsutani Y, et al
    The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
    Lung Cancer. 2021;158:9-14.
    PubMed     Abstract available


  29. HE LN, Fu S, Zhang X, Hu Q, et al
    Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    Lung Cancer. 2021;158:1-8.
    PubMed     Abstract available


  30. LAVOLE A, Mazieres J, Schneider S, Brosseau S, et al
    Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
    Lung Cancer. 2021;158:146-150.
    PubMed     Abstract available


  31. DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
    Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
    Lung Cancer. 2021;158:40-46.
    PubMed     Abstract available


  32. GOKER E, Altwairgi A, Al-Omair A, Tfayli A, et al
    Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
    Lung Cancer. 2021;158:60-73.
    PubMed     Abstract available


  33. LIU R, Ota K, Iwama E, Yoneshima Y, et al
    Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
    Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
    PubMed     Abstract available


  34. OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
    Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
    Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.
    PubMed    


  35. DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
    Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
    PubMed     Abstract available


  36. PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
    Lung cancer patients with COVID-19 in Spain: GRAVID study.
    Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
    PubMed     Abstract available


  37. WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
    Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
    PubMed     Abstract available


  38. PILLERON S, Maringe C, Charvat H, Atkinson J, et al
    Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
    PubMed     Abstract available


  39. ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
    FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
    Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
    PubMed     Abstract available


  40. LEI H, Yang Y, Zhou W, Zhang M, et al
    Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
    Lung Cancer. 2021 May 5. pii: S0169-5002(21)00170.
    PubMed     Abstract available


  41. WANG LL, Yu H, Wang HY, Liu T, et al
    Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2021 May 3. pii: S0169-5002(21)00168.
    PubMed    


  42. OSAROGIAGBON RU
    The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.
    Lung Cancer. 2021;155:191-192.
    PubMed    


  43. HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
    Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Lung Cancer. 2021;155:175-182.
    PubMed     Abstract available


  44. SUMI T, Nakata H, Chiba H
    Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
    Lung Cancer. 2021;155:196-198.
    PubMed    


  45. LUO Y, Wei J, Zhang J, Zeng L, et al
    Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Lung Cancer. 2021;155:170-174.
    PubMed     Abstract available


  46. NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
    Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2021;155:163-169.
    PubMed     Abstract available


  47. VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
    Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
    Lung Cancer. 2021;155:156-162.
    PubMed     Abstract available


  48. LV W, Wang Y, Zhou C, Yuan M, et al
    Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
    Lung Cancer. 2021;155:78-86.
    PubMed     Abstract available


  49. ZHAO D, Hou F, Li M, Qi Y, et al
    A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
    Lung Cancer. 2021;155:193-195.
    PubMed    


  50. MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
    Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Lung Cancer. 2021;155:10-19.
    PubMed     Abstract available


  51. FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
    Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
    Lung Cancer. 2021;155:1-9.
    PubMed     Abstract available


  52. ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
    Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
    Lung Cancer. 2021;155:183-190.
    PubMed     Abstract available


    April 2021
  53. DEBIEUVRE D, Juergens RA, Asselain B, Audigier-Valette C, et al
    Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Lung Cancer. 2021 Apr 30. pii: S0169-5002(21)00165.
    PubMed     Abstract available


  54. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
    Lung Cancer. 2021;156:82-90.
    PubMed     Abstract available


  55. NEWMAN NB, Osmundson EC
    Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
    Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
    PubMed     Abstract available


  56. FROESCH P, Mark M, Rothschild SI, Li Q, et al
    Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
    Lung Cancer. 2021;156:91-99.
    PubMed     Abstract available


  57. PALL G, Gautschi O
    Advances in the treatment of RET-fusion-positive lung cancer.
    Lung Cancer. 2021 Apr 24. pii: S0169-5002(21)00159.
    PubMed     Abstract available


  58. KUZDZAL J, Trybalski L, Hauer L, Cmiel A, et al
    Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study.
    Lung Cancer. 2021 Apr 22. pii: S0169-5002(21)00160.
    PubMed     Abstract available


  59. TAMMEMAGI MC, Darling GE, Schmidt H, Llovet D, et al
    Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Lung Cancer. 2021;156:31-40.
    PubMed     Abstract available


  60. ZHANG CC, Hou RP, Xia WY, Zeng WQ, et al
    Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study.
    Lung Cancer. 2021;156:100-108.
    PubMed     Abstract available


  61. HORIUCHI K, Sato T, Kuno T, Takagi H, et al
    Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;156:59-67.
    PubMed     Abstract available


  62. BOGART JA, Wang X, Masters GA, Gao J, et al
    Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
    Lung Cancer. 2021;156:68-71.
    PubMed     Abstract available


  63. HSU CL, Tsai TH, Huang CK, Yang CY, et al
    Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
    Lung Cancer. 2021;156:50-58.
    PubMed     Abstract available


  64. VON DER THUSEN JH, Dumoulin DW, Maat APWM, Wolf J, et al
    ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype.
    Lung Cancer. 2021;156:72-75.
    PubMed     Abstract available


  65. MILLER HA, Yin X, Smith SA, Hu X, et al
    Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
    Lung Cancer. 2021;156:20-30.
    PubMed     Abstract available


  66. ITO S, Asahina H, Honjo O, Tanaka H, et al
    Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
    Lung Cancer. 2021;156:12-19.
    PubMed     Abstract available


  67. WATERHOUSE D, Lam J, Betts KA, Yin L, et al
    Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Lung Cancer. 2021;156:41-49.
    PubMed     Abstract available


  68. SCHREUDER A, Mets OM, Schaefer-Prokop CM, Jacobs C, et al
    Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Lung Cancer. 2021;156:5-11.
    PubMed     Abstract available


  69. VISSER MPJ, van Grimbergen I, Holters J, Barendregt WB, et al
    Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer.
    Lung Cancer. 2021 Apr 7. pii: S0169-5002(21)00132.
    PubMed     Abstract available


  70. YANG L, Zhao W, Zhu H, Li X, et al
    PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;154:219-220.
    PubMed    


  71. COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
    Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
    Lung Cancer. 2021;154:146-150.
    PubMed     Abstract available


  72. VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
    Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Lung Cancer. 2021;154:131-141.
    PubMed     Abstract available


  73. XIONG A, Li C, Xu J, Yang X, et al
    Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Lung Cancer. 2021;154:124-130.
    PubMed     Abstract available


  74. SHANG X, Li Z, Sun J, Zhao C, et al
    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Lung Cancer. 2021;154:105-112.
    PubMed     Abstract available


  75. WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
    Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Lung Cancer. 2021;154:216-218.
    PubMed    


  76. ZHANG C, Wang H
    Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
    Lung Cancer. 2021;154:221-223.
    PubMed    


  77. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Lung Cancer. 2021;154:92-98.
    PubMed     Abstract available


  78. ZHANG C, Wang H
    The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
    Lung Cancer. 2021;154:214-215.
    PubMed    


  79. WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
    Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
    Lung Cancer. 2021;154:76-83.
    PubMed     Abstract available


  80. LI Z, Li F, Pan C, He Z, et al
    Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
    Lung Cancer. 2021;154:69-75.
    PubMed     Abstract available


  81. COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
    Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
    Lung Cancer. 2021;154:23-28.
    PubMed     Abstract available


  82. KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
    Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Lung Cancer. 2021;154:5-12.
    PubMed     Abstract available


  83. PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
    Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
    Lung Cancer. 2021;154:186-194.
    PubMed     Abstract available


    March 2021
  84. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed     Abstract available


  85. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed     Abstract available


  86. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed     Abstract available


  87. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed     Abstract available


  88. EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
    Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;155:103-113.
    PubMed     Abstract available


  89. TAO J, Jatoi A, Crawford J, Lam WWT, et al
    Role of dietary carbohydrates on risk of lung cancer.
    Lung Cancer. 2021;155:87-93.
    PubMed     Abstract available


  90. YUN JK, Lee GD, Choi S, Kim HR, et al
    The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.
    Lung Cancer. 2021;155:94-102.
    PubMed     Abstract available


  91. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed     Abstract available


  92. AREDO JV, Purington N, Su L, Luo SJ, et al
    Metabolomic profiling for second primary lung cancer: A pilot case-control study.
    Lung Cancer. 2021;155:61-67.
    PubMed     Abstract available


  93. DAMHUS CS, Quentin JG, Malmqvist J, Siersma V, et al
    Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey.
    Lung Cancer. 2021;155:46-52.
    PubMed     Abstract available


  94. YOH K, Seto T, Satouchi M, Nishio M, et al
    Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
    Lung Cancer. 2021;155:40-45.
    PubMed     Abstract available


  95. LIU J, Itchins M, Nagrial A, Cooper WA, et al
    Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2021;155:28-33.
    PubMed     Abstract available


  96. WANG W, Xu C, Chen H, Jia J, et al
    Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Lung Cancer. 2021;155:20-27.
    PubMed     Abstract available


  97. GARCIA CAMPELO MR, Lin HM, Zhu Y, Perol M, et al
    Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+non-small cell lung cancer (ALTA-1L).
    Lung Cancer. 2021;155:68-77.
    PubMed     Abstract available


  98. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
    Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.
    PubMed    


  99. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed     Abstract available


  100. ATTILI I, Tarantino P, Passaro A, Stati V, et al
    Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Lung Cancer. 2021;154:151-160.
    PubMed     Abstract available


  101. MORAES FY, Mansouri A, Dasgupta A, Ramotar M, et al
    Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
    Lung Cancer. 2021;155:34-39.
    PubMed     Abstract available


  102. KUNIMASA K
    A reply to "Cardiac dysfunction due to Osimertinib".
    Lung Cancer. 2021;153:195.
    PubMed    


  103. BOMMART S, Pujol JL, Coffy A, Daures JP, et al
    Authors reply to letter to the editor by Dr Degens et al.
    Lung Cancer. 2021;153:185.
    PubMed    


  104. ANAND K
    Cardiac dysfunction due to Osimertinib.
    Lung Cancer. 2021;153:193-194.
    PubMed    


  105. BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
    Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
    Lung Cancer. 2021;153:182-183.
    PubMed    


  106. ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
    Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
    Lung Cancer. 2021;153:158-164.
    PubMed     Abstract available


  107. FUCHS V, Roisman L, Kian W, Daniel L, et al
    The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Lung Cancer. 2021;153:126-133.
    PubMed     Abstract available


  108. LI R, Jiang L, Zhou X, Lu Y, et al
    Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
    Lung Cancer. 2021;153:120-125.
    PubMed     Abstract available


  109. MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
    Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
    Lung Cancer. 2021;153:117-119.
    PubMed     Abstract available


  110. ZHAI X, Wu Q, Zeng Z, Suo J, et al
    OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:171-173.
    PubMed    


  111. WANG B, Chen R, Wang C, Chen H, et al
    PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:176-178.
    PubMed    


  112. REN P, Luo N, Qi Y, Wu Y, et al
    A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Lung Cancer. 2021;153:179-181.
    PubMed    


  113. DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
    RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
    Lung Cancer. 2021;153:90-98.
    PubMed     Abstract available


  114. LIU Y, Gao GF, Minna JD, Williams NS, et al
    Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
    Lung Cancer. 2021;153:73-80.
    PubMed     Abstract available


  115. ZHOU F, Huang Y, Cai W, Li J, et al
    The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Lung Cancer. 2021;153:66-72.
    PubMed     Abstract available


  116. AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
    Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Lung Cancer. 2021;153:56-65.
    PubMed     Abstract available


  117. CHIA PL, Parakh S, Russell P, Gan HK, et al
    Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
    Lung Cancer. 2021;153:35-41.
    PubMed     Abstract available


  118. SUZUKI J, Aokage K, Neri S, Sakai T, et al
    Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Lung Cancer. 2021;153:1-10.
    PubMed     Abstract available


  119. KUNIMASA K, Oka T, Hara S, Yamada N, et al
    Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
    Lung Cancer. 2021;153:186-192.
    PubMed     Abstract available


    February 2021
  120. LIU L, Bai H, Seery S, Li S, et al
    Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.
    Lung Cancer. 2021;158:74-84.
    PubMed     Abstract available


  121. LIU G, Brenner H, Chen C, Christiani D, et al
    A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?"
    Lung Cancer. 2021 Feb 26. pii: S0169-5002(21)00079.
    PubMed    


  122. WONG SK, Alex D, Bosdet I, Hughesman C, et al
    MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Lung Cancer. 2021;154:142-145.
    PubMed     Abstract available


  123. CHENG Y, Mok TS, Zhou X, Lu S, et al
    Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Lung Cancer. 2021;154:176-185.
    PubMed     Abstract available


  124. FOURDRAIN A, Epailly J, Blanchard C, Georges O, et al
    Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura.
    Lung Cancer. 2021;154:118-123.
    PubMed     Abstract available


  125. KOK PS, Lee K, Lord S, Yang JC, et al
    Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
    Lung Cancer. 2021;154:113-117.
    PubMed     Abstract available


  126. KERR KM, Bibeau F, Thunnissen E, Botling J, et al
    The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Lung Cancer. 2021;154:161-175.
    PubMed     Abstract available


  127. MAO K, Liu F, Liu X, Khuri FR, et al
    Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
    Lung Cancer. 2021 Feb 19. pii: S0169-5002(21)00073.
    PubMed    


  128. GARON EB, Aerts J, Kim JS, Muehlenbein CE, et al
    Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Lung Cancer. 2021;155:53-60.
    PubMed     Abstract available


  129. OHARA S, Suda K, Fujino T, Hamada A, et al
    Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.
    Lung Cancer. 2021;154:84-91.
    PubMed     Abstract available


  130. LIU F, Liu Y, Liu X, Mao K, et al
    Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
    Lung Cancer. 2021 Feb 18. pii: S0169-5002(21)00072.
    PubMed    


  131. CHENG H, Zou Y, Shah CD, Fan N, et al
    First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;154:99-104.
    PubMed     Abstract available


  132. AHMED Z, Kennedy K, Subramanian J
    The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
    Lung Cancer. 2021;154:62-68.
    PubMed     Abstract available


  133. CHEN X, Muhammad KG, Madeeha C, Fu W, et al
    Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
    Lung Cancer. 2021 Feb 14. pii: S0169-5002(21)00065.
    PubMed     Abstract available


  134. SEBASTIAN M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, et al
    KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2021;154:51-61.
    PubMed     Abstract available


  135. HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
    A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
    Lung Cancer. 2021;154:13-22.
    PubMed     Abstract available


  136. SPAGGIARI L, Bertolaccini L, Facciolo F, Gallina FT, et al
    A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Lung Cancer. 2021;154:29-35.
    PubMed     Abstract available


  137. LAMOTE K, Van den Heuvel MM
    Where the nose is going to help the eye: Sniffing lung cancer.
    Lung Cancer. 2021 Feb 10. pii: S0169-5002(21)00063.
    PubMed    


  138. PALLARI E, Eriksson M, Billhult A, Billhult T, et al
    Lung cancer research and its citation on clinical practice guidelines.
    Lung Cancer. 2021;154:44-50.
    PubMed     Abstract available


  139. WANG S, Chen H, Zhong J, Qin H, et al
    Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
    Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.
    PubMed    


  140. CAI C, Tang Y, Li Y, Chen Y, et al
    Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Lung Cancer. 2021;152:104-108.
    PubMed     Abstract available


  141. LI X, Liu J, Guo M, Cai H, et al
    NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
    Lung Cancer. 2021;152:202-204.
    PubMed    


  142. LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
    Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
    Lung Cancer. 2021;152:157-164.
    PubMed     Abstract available


  143. ZHAO G, Chen L, Xiao M, Yang S, et al
    Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Lung Cancer. 2021;152:189-192.
    PubMed    


  144. MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
    Subclinical myasthenia gravis in thymomas.
    Lung Cancer. 2021;152:143-148.
    PubMed     Abstract available


  145. HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
    Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Lung Cancer. 2021;152:135-142.
    PubMed     Abstract available


  146. LIANG P, Qi L, Guo T, You X, et al
    A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Lung Cancer. 2021;152:193-195.
    PubMed    


  147. MA H, Zhang Q, Duan Q, Zhang Q, et al
    Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Lung Cancer. 2021;152:196-198.
    PubMed    


  148. BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
    Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Lung Cancer. 2021;152:119-126.
    PubMed     Abstract available


  149. GENDARME S, Matton L, Antoine M, Kerrou K, et al
    Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
    Lung Cancer. 2021;152:94-97.
    PubMed     Abstract available


  150. BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
    CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
    Lung Cancer. 2021;152:34-38.
    PubMed     Abstract available


  151. CHAE M, Jeon JH, Chung JH, Lee SY, et al
    Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
    Lung Cancer. 2021;152:21-26.
    PubMed     Abstract available


  152. KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
    Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
    Lung Cancer. 2021;152:15-20.
    PubMed     Abstract available


  153. GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
    Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
    Lung Cancer. 2021;152:1-6.
    PubMed     Abstract available


    January 2021
  154. HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
    Lung cancer prediction by Deep Learning to identify benign lung nodules.
    Lung Cancer. 2021;154:1-4.
    PubMed     Abstract available


  155. ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
    Breath profile as composite biomarkers for lung cancer diagnosis.
    Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
    PubMed     Abstract available


  156. GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
    Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
    Lung Cancer. 2021;153:165-170.
    PubMed     Abstract available


  157. FRIEDES C, Chakrabarti T, Olson S, Prichett L, et al
    Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
    Lung Cancer. 2021;154:36-43.
    PubMed     Abstract available


  158. EICHHORN F, Klotz LV, Kriegsmann M, Bischoff H, et al
    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Lung Cancer. 2021;153:150-157.
    PubMed     Abstract available


  159. CHU X, Zhao J, Zhou J, Zhou F, et al
    Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020
    Lung Cancer. 2021 Jan 15. pii: S0169-5002(21)00015.
    PubMed    


  160. HASHEMI S, Fransen MF, Niemeijer A, Ben Taleb N, et al
    Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
    Lung Cancer. 2021;153:81-89.
    PubMed     Abstract available


  161. ZHOU J, Yu X, Hou L, Zhao J, et al
    Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
    Lung Cancer. 2021;153:143-149.
    PubMed     Abstract available


  162. TAKAGI H, Zhao S, Muto S, Yokouchi H, et al
    Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
    Lung Cancer. 2021;153:134-142.
    PubMed     Abstract available


  163. CHEN D, Kang P, Tao S, Li Q, et al
    Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
    Lung Cancer. 2021;153:99-107.
    PubMed     Abstract available


  164. OHTAKI Y, Shimizu K, Suzuki H, Suzuki K, et al
    Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;153:108-116.
    PubMed     Abstract available


  165. IKEDA T, Kadota K, Yoshida C, Ishikawa R, et al
    The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinoma.
    Lung Cancer. 2021;153:49-55.
    PubMed     Abstract available


  166. PROVENCIO M, Majem M, Guirado M, Massuti B, et al
    Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of su
    Lung Cancer. 2021;153:25-34.
    PubMed     Abstract available


  167. SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
    Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.
    Lung Cancer. 2021;153:42-48.
    PubMed     Abstract available


  168. LI Z, Lin Y, Chi X, Xu M, et al
    Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
    Lung Cancer. 2021 Jan 8. pii: S0169-5002(21)00007.
    PubMed    


  169. BRACKEN-CLARKE D, Kapoor D, Baird AM, Buchanan PJ, et al
    Vaping and lung cancer - A review of current data and recommendations.
    Lung Cancer. 2021;153:11-20.
    PubMed     Abstract available


  170. YANG ZY, Liu ZY, Mu CY, Jiang JH, et al
    Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:97.
    PubMed    


  171. LI X, Zhang D, Li B, Zou B, et al
    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Lung Cancer. 2021;151:39-43.
    PubMed     Abstract available


  172. FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
    Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Lung Cancer. 2021;151:30-38.
    PubMed     Abstract available


  173. LI M, Tang Q, Chen S, Wang Y, et al
    A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Lung Cancer. 2021;151:98-100.
    PubMed    


  174. BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
    Risk of second primary malignancies among patients with carcinoid of the lung.
    Lung Cancer. 2021;151:5-7.
    PubMed     Abstract available


  175. XIONG L, Li X, Chen D, Li S, et al
    GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:104-105.
    PubMed    


  176. TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
    Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
    Lung Cancer. 2021;151:1-4.
    PubMed     Abstract available


  177. BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
    PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Lung Cancer. 2021;151:69-75.
    PubMed     Abstract available


  178. WANG H, Shan Q, Guo J, Han X, et al
    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Lung Cancer. 2021;151:76-83.
    PubMed     Abstract available


    December 2020
  179. DURHAM DD, Croswell JM, Marcus PM
    Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
    Lung Cancer. 2020;153:21-24.
    PubMed     Abstract available


  180. ABBAR B, De Castelbajac V, Gougis P, Assoun S, et al
    Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:109-118.
    PubMed     Abstract available


  181. LOBEFARO R, Viscardi G, Di Liello R, Massa G, et al
    Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
    Lung Cancer. 2020;152:165-173.
    PubMed     Abstract available


  182. RONDEN MI, Bahce I, Hashemi SMS, Dickhoff C, et al
    Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
    Lung Cancer. 2020;152:149-156.
    PubMed     Abstract available


  183. BRAILLON A
    Lung cancer outcomes: Are BMI and race clinically relevant?
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30749.
    PubMed    


  184. SHIBATA Y, Matsumoto S, Yoh K, Goto K, et al
    Evaluation of variant frequency in SARS-CoV-2 infection-related genes utilizing lung cancer genomic database.
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30733.
    PubMed    


  185. CASIRAGHI M, Sedda G, Del Signore E, Piperno G, et al
    Surgery for small cell lung cancer: When and how.
    Lung Cancer. 2020;152:71-77.
    PubMed     Abstract available


  186. MATSUURA Y, Ichinose J, Nakao M, Ninomiya H, et al
    Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
    Lung Cancer. 2020;152:78-85.
    PubMed     Abstract available


  187. DE MARINIS F, Laktionov KK, Poltoratskiy A, Egorova I, et al
    Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    Lung Cancer. 2020;152:127-134.
    PubMed     Abstract available


  188. THOMAS PA, Couderc AL, Boulate D, Greillier L, et al
    Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?
    Lung Cancer. 2020;152:86-93.
    PubMed     Abstract available


  189. PENG W, Pu X, Jiang M, Wang J, et al
    Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Lung Cancer. 2020;152:66-70.
    PubMed     Abstract available


  190. YANG X, Man J, Chen H, Zhang T, et al
    Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis.
    Lung Cancer. 2020;152:49-57.
    PubMed     Abstract available


  191. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:27-33.
    PubMed     Abstract available


  192. JIANG M, Fares AF, Shepshelovich D, Yang P, et al
    The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
    Lung Cancer. 2020;152:58-65.
    PubMed     Abstract available


  193. YANG GJ, Li J, Xu HY, Sun Y, et al
    Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Lung Cancer. 2020;152:39-48.
    PubMed     Abstract available


  194. VIGARIOS E, Rabeau A, Mazieres J, Sibaud V, et al
    Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management.
    Lung Cancer. 2020 Dec 4. pii: S0169-5002(20)30714.
    PubMed    


  195. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
    Lung Cancer. 2020 Dec 2. pii: S0169-5002(20)30691.
    PubMed    


  196. MI J, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:259-260.
    PubMed    


  197. LIU L, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:254-255.
    PubMed    


  198. LI X, Wang R, Wang L
    MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:256-258.
    PubMed    


  199. LI X, Wang L, Yu J
    ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:252-253.
    PubMed    


    November 2020
  200. ELFVING H, Brostrom E, Moens LNJ, Almlof J, et al
    Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Lung Cancer. 2020;151:53-59.
    PubMed     Abstract available


  201. MCCANN B, Muhr R, O'Rourke N, Milroy R, et al
    ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.
    Lung Cancer. 2020;151:44-52.
    PubMed     Abstract available


  202. LU S, Wang J, Cheng Y, Mok T, et al
    Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
    Lung Cancer. 2020;152:7-14.
    PubMed     Abstract available


  203. GARON EB, Kim JS, Govindan R
    Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
    Lung Cancer. 2020;151:25-29.
    PubMed     Abstract available


  204. YAMAMOTO N, Seto T, Nishio M, Goto K, et al
    Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
    Lung Cancer. 2020;151:20-24.
    PubMed     Abstract available


  205. ARAKAWA S, Yoshida T, Shirasawa M, Takayanagi D, et al
    RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
    Lung Cancer. 2020 Nov 20. pii: S0169-5002(20)30690.
    PubMed    


  206. LEE Y, Joo J, Lee YJ, Lee EK, et al
    Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2020;151:8-15.
    PubMed     Abstract available


  207. SONI S, Rastogi A, Prasad KT, Behera D, et al
    Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
    Lung Cancer. 2020;151:16-19.
    PubMed     Abstract available


  208. TSITSIAS T, Okiror L, Veres L, King J, et al
    New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.
    Lung Cancer. 2020 Nov 16. pii: S0169-5002(20)30680.
    PubMed     Abstract available


  209. WAKUDA K, Yabe M, Kodama H, Nishioka N, et al
    Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
    Lung Cancer. 2020 Nov 15. pii: S0169-5002(20)30684.
    PubMed     Abstract available


  210. WANG M, Zhang D, Wang G, Xia J, et al
    HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
    Lung Cancer. 2020 Nov 13. pii: S0169-5002(20)30679.
    PubMed    


  211. JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
    Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Lung Cancer. 2020;150:209-215.
    PubMed     Abstract available


  212. ZHOU Y, Wang B, Qu J, Yu F, et al
    Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2020;150:178-185.
    PubMed     Abstract available


  213. VICKERS AJ, Frese K, Galvin M, Carter M, et al
    Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
    Lung Cancer. 2020;150:216-220.
    PubMed     Abstract available


  214. GASSA A, Fassunke J, Schueten S, Kuhlmann L, et al
    Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Lung Cancer. 2020 Nov 5. pii: S0169-5002(20)30670.
    PubMed     Abstract available


  215. WU YL, Shi Y, Tan DSW, Xiaoqing L, et al
    Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Lung Cancer. 2020;150:240-246.
    PubMed     Abstract available


  216. LI JJN, Karim K, Sung M, Le LW, et al
    Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
    Lung Cancer. 2020;150:159-163.
    PubMed     Abstract available


  217. BISHNOI R, Shah C, Blaes A, Bian J, et al
    Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Lung Cancer. 2020;150:172-177.
    PubMed     Abstract available


  218. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2020 Nov 2. pii: S0169-5002(20)30663.
    PubMed     Abstract available


    October 2020
  219. YUN JK, Park I, Kim HR, Choi YS, et al
    Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
    Lung Cancer. 2020;150:201-208.
    PubMed     Abstract available


  220. BERSANELLI M, Buti S, Giannarelli D, Leonetti A, et al
    Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
    Lung Cancer. 2020;150:123-131.
    PubMed     Abstract available


  221. FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Lung Cancer. 2020;150:114-122.
    PubMed     Abstract available


  222. ZENG C, Gao Y, Xiong J, Lu J, et al
    Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
    Lung Cancer. 2020;150:139-144.
    PubMed     Abstract available


  223. YOTSUKURA M, Asamura H, Suzuki S, Asakura K, et al
    Corrigendum to "Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma" [Lung Cancer 145 (2020) 158-166].
    Lung Cancer. 2020 Oct 13. pii: S0169-5002(20)30639.
    PubMed    


  224. SUBBIAH V, Paz-Ares L, Besse B, Moreno V, et al
    Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Lung Cancer. 2020;150:90-96.
    PubMed     Abstract available


  225. WANG L, Ruan M, Lei B, Yan H, et al
    The potential of (18)F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
    Lung Cancer. 2020;150:44-52.
    PubMed     Abstract available


  226. ZENG J, Mao WM, Chen QX, Luo TB, et al
    Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Lung Cancer. 2020;150:164-171.
    PubMed     Abstract available


  227. GARCIA-CAMPELO R, Arrieta O, Massuti B, Rodriguez-Abreu D, et al
    Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Lung Cancer. 2020;150:62-69.
    PubMed     Abstract available


  228. INAGAKI Y, Tamiya A
    Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.
    Lung Cancer. 2020;148:179-180.
    PubMed    


    September 2020
  229. SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
    Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Lung Cancer. 2020;149:137-143.
    PubMed     Abstract available


  230. TAO H, Shi L, Zhou A, Li H, et al
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2020;149:154-161.
    PubMed     Abstract available


  231. ZHANG L, Yip R, Jirapatnakul A, Li M, et al
    Lung cancer screening intervals based on cancer risk.
    Lung Cancer. 2020;149:113-119.
    PubMed     Abstract available


  232. TAKEDA-MIYATA N, Konishi E, Tanaka T, Shimomura M, et al
    Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer.
    Lung Cancer. 2020;149:61-67.
    PubMed     Abstract available


  233. FUKUMOTO K, Mori S, Shintani Y, Okami J, et al
    Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study.
    Lung Cancer. 2020;149:120-129.
    PubMed     Abstract available


  234. GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung Cancer. 2020;149:46-52.
    PubMed     Abstract available


  235. REISSIG TM, Sara L, Ting S, Reis H, et al
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
    Lung Cancer. 2020;149:10-16.
    PubMed     Abstract available


  236. LIU X, Hong L, Nilsson M, Hubert SM, et al
    Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2020;149:33-40.
    PubMed     Abstract available


  237. LI J, Wang Y, Zhang B, Xu J, et al
    Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Lung Cancer. 2020;149:17-22.
    PubMed     Abstract available


  238. ALBORELLI I, Bratic Hench I, Chijioke O, Prince SS, et al
    Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Lung Cancer. 2020;149:84-89.
    PubMed     Abstract available


  239. VOONG KR, Naidoo J
    Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
    Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.
    PubMed    


  240. BERGHMANS T, Lievens Y, Aapro M, Baird AM, et al
    European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
    Lung Cancer. 2020;150:221-239.
    PubMed     Abstract available


    August 2020
  241. BAUM P, Diers J, Haag J, Klotz L, et al
    Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany.
    Lung Cancer. 2020;149:78-83.
    PubMed     Abstract available


  242. CHU X, Zhao J, Zhou J, Zhou F, et al
    Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Lung Cancer. 2020;150:76-82.
    PubMed     Abstract available


  243. CHRISTOPOULOS P, Kirchner M, Roeper J, Saalfeld F, et al
    Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.
    Lung Cancer. 2020;148:105-112.
    PubMed     Abstract available


  244. SUDA K, Murakami I, Obata K, Sakai K, et al
    Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
    Lung Cancer. 2020;148:100-104.
    PubMed     Abstract available


  245. ISMAIL RK, Schramel FMNH, van Dartel M, Hilarius DL, et al
    The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.
    Lung Cancer. 2020;149:68-77.
    PubMed     Abstract available


  246. ANG L, Chan CPY, Yau WP, Seow WJ, et al
    Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis.
    Lung Cancer. 2020;148:129-137.
    PubMed     Abstract available


  247. YAMAMOTO M, Serizawa T, Sato Y, Higuchi Y, et al
    Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.
    Lung Cancer. 2020;149:103-112.
    PubMed     Abstract available


  248. VAN VEGGEL B, de Langen AJ
    A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
    Lung Cancer. 2020 Aug 8. pii: S0169-5002(20)30555.
    PubMed    


  249. RECK M, Syrigos K, Miliauskas S, Zochbauer-Muller S, et al
    Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Lung Cancer. 2020;148:159-165.
    PubMed     Abstract available


  250. WADDLE MR, Ko SJ, May J, Kaleem T, et al
    Improving identification of candidates for lung cancer screening in a high risk population.
    Lung Cancer. 2020;148:79-85.
    PubMed     Abstract available


  251. MADISON R, Schrock AB, Castellanos E, Gregg JP, et al
    Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Lung Cancer. 2020;148:69-78.
    PubMed     Abstract available


  252. SURYAVANSHI M, Jaipuria J, Panigrahi MK, Goyal N, et al
    CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
    Lung Cancer. 2020;148:33-39.
    PubMed     Abstract available


  253. MARCHIONI A, Andrisani D, Tonelli R, Piro R, et al
    Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
    Lung Cancer. 2020;148:40-47.
    PubMed     Abstract available


  254. CHANG HL, Wei PJ, Wu KL, Huang HL, et al
    Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Lung Cancer. 2020;146:376-377.
    PubMed    


  255. WANG K, Liu Y, Hu T, Liu Y, et al
    The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
    Lung Cancer. 2020;146:373-375.
    PubMed    


    July 2020
  256. BARTLETT EC, Kemp SV, Ridge CA, Desai SR, et al
    Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
    Lung Cancer. 2020;148:12-19.
    PubMed     Abstract available


  257. ROJO F, Corassa M, Mavroudis D, Oz AB, et al
    International real-world study of DLL3 expression in patients with small cell lung cancer.
    Lung Cancer. 2020;147:237-243.
    PubMed     Abstract available


  258. YOUNG K, Jiang H, Marquez M, Yeung J, et al
    Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;147:214-220.
    PubMed     Abstract available


  259. VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
    Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
    Lung Cancer. 2020;147:244-251.
    PubMed     Abstract available


  260. YANG G, Xu H, Yang L, Xu F, et al
    Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Lung Cancer. 2020;147:229-236.
    PubMed     Abstract available


  261. ZHENG J, Cao H, Li Y, Rao C, et al
    Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Lung Cancer. 2020;147:130-136.
    PubMed     Abstract available


  262. FAN Y, Chen J, Zhou C, Wang H, et al
    Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Lung Cancer. 2020;147:209-213.
    PubMed     Abstract available


  263. VARLOTTO JM, Voland R, DeCamp MM, Rava P, et al
    The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer.
    Lung Cancer. 2020;147:115-122.
    PubMed     Abstract available


  264. BEN DORI S, Aizic A, Sabo E, Hershkovitz D, et al
    Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Lung Cancer. 2020;147:91-98.
    PubMed     Abstract available


  265. SVEDBERG A, Bjorn N, Sigurgeirsson B, Pradhananga S, et al
    Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
    Lung Cancer. 2020;147:106-114.
    PubMed     Abstract available


  266. TOUMAZIS I, Bastani M, Han SS, Plevritis SK, et al
    Risk-Based lung cancer screening: A systematic review.
    Lung Cancer. 2020;147:154-186.
    PubMed     Abstract available


  267. JIA XH, Xu H, Geng LY, Jiao M, et al
    Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2020;147:143-153.
    PubMed     Abstract available


  268. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Corrigendum to "Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer" [Lung Cancer 142 (2020) 28-33].
    Lung Cancer. 2020 Jul 8. pii: S0169-5002(20)30485.
    PubMed    


  269. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery.
    Lung Cancer. 2020;147:71-76.
    PubMed     Abstract available


  270. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing".
    Lung Cancer. 2020 Jul 3. pii: S0169-5002(20)30515.
    PubMed    


  271. REMON J, Nadal E, Domine M, Ruffinelli J, et al
    Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Lung Cancer. 2020;147:83-90.
    PubMed     Abstract available


  272. WANG Q, Li X, Ren S, Su C, et al
    HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Lung Cancer. 2020;147:99-105.
    PubMed     Abstract available


  273. DI NOIA V, D'Aveni A, Squadroni M, Beretta GD, et al
    Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
    Lung Cancer. 2020;145:208-210.
    PubMed    


  274. CHEN H, Louie AV
    High risk, same reward?
    Lung Cancer. 2020;145:221.
    PubMed    


  275. BALDINI E, Tibaldi C
    A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
    Lung Cancer. 2020;145:226.
    PubMed    


  276. INDINI A, Rijavec E, Grossi F
    Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
    Lung Cancer. 2020;145:225.
    PubMed    


    June 2020
  277. CORSINI EM, Wang Q, Tran HT, Mitchell KG, et al
    Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
    Lung Cancer. 2020;146:303-309.
    PubMed     Abstract available


  278. CUI W, Franchini F, Alexander M, Officer A, et al
    Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Lung Cancer. 2020;146:310-317.
    PubMed     Abstract available


  279. SUNG JH, Brown MC, Perez-Cosio A, Pratt L, et al
    Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study.
    Lung Cancer. 2020;147:1-11.
    PubMed     Abstract available


  280. GACHECHILADZE M, Skarda J, Skanderova D, Uberall I, et al
    Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Lung Cancer. 2020;147:30-38.
    PubMed     Abstract available


  281. CHEN C, Wang W, Yu Z, Tian S, et al
    Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.
    Lung Cancer. 2020;146:290-296.
    PubMed     Abstract available


  282. SOMMER MS, Vibe-Petersen J, Staerkind MB, Langer SW, et al
    Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.
    Lung Cancer. 2020;146:285-289.
    PubMed     Abstract available


  283. LU S, Chen G, Sun Y, Sun S, et al
    A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lung Cancer. 2020;146:252-262.
    PubMed     Abstract available


  284. HURKMANS DP, Tamminga M, van Es B, Peters T, et al
    Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
    Lung Cancer. 2020;146:341-349.
    PubMed     Abstract available


  285. CHEN LN, Spivack J, Cao T, Saqi A, et al
    Characteristics and outcomes of lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;146:297-302.
    PubMed     Abstract available


  286. WANG Z, Zhao J, Ma Z, Cui J, et al
    A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Lung Cancer. 2020;147:259-268.
    PubMed     Abstract available


  287. KOBAYASHI K, Soejima K, Fukunaga K, Shintani Y, et al
    Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
    Lung Cancer. 2020;146:236-243.
    PubMed     Abstract available


  288. WANG W, Cheng G, Zhang G, Song Z, et al
    Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
    Lung Cancer. 2020;146:224-229.
    PubMed     Abstract available


  289. GAGNE A, Orain M, Ionescu D, Tsao MS, et al
    Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Lung Cancer. 2020;146:276-284.
    PubMed     Abstract available


  290. NICOSIA L, Di Muzio J, Agolli L, Alongi F, et al
    What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?
    Lung Cancer. 2020;146:263-275.
    PubMed     Abstract available


  291. HUANG M, Insinga RP, Burke T, Zhang Y, et al
    In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
    Lung Cancer. 2020 Jun 17. pii: S0169-5002(20)30489.
    PubMed    


  292. LEI Y, Feng H, Qiang H, Shang Z, et al
    Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.
    Lung Cancer. 2020;146:244-251.
    PubMed     Abstract available


  293. LU M, Hu C, Wu F, Shu L, et al
    MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
    Lung Cancer. 2020;147:193-197.
    PubMed     Abstract available


  294. STAHEL RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, et al
    Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug.
    Lung Cancer. 2020;146:217-223.
    PubMed     Abstract available


  295. IGAWA S, Naoki K, Shintani Y, Sekine I, et al
    Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
    Lung Cancer. 2020;146:160-164.
    PubMed     Abstract available


  296. MENG P, Koopman B, Kok K, Ter Elst A, et al
    Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Lung Cancer. 2020 Jun 4. pii: S0169-5002(20)30472.
    PubMed     Abstract available


  297. FORNACON-WOOD I, Faivre-Finn C, O'Connor JPB, Price GJ, et al
    Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.
    Lung Cancer. 2020;146:197-208.
    PubMed     Abstract available


  298. CHEN D, Chen C, Chen Y
    Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
    Lung Cancer. 2020;144:92.
    PubMed    


    May 2020
  299. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed     Abstract available


  300. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed     Abstract available


  301. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed     Abstract available


  302. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed     Abstract available


  303. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed     Abstract available


  304. ZHENG J, Zhu Y, Sun K, Shen Q, et al
    Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Lung Cancer. 2020;146:209-216.
    PubMed     Abstract available


  305. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed     Abstract available


  306. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed     Abstract available


  307. LIAO Z, Rivin Del Campo E, Salem A, Pang Q, et al
    Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.
    Lung Cancer. 2020;146:230-235.
    PubMed     Abstract available


  308. TESSEMA M, Tassew DD, Yingling CM, Do K, et al
    Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.
    Lung Cancer. 2020;146:189-196.
    PubMed     Abstract available


  309. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed     Abstract available


  310. LEAL JL, Peters G, Szaumkessel M, Leong T, et al
    NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Lung Cancer. 2020;146:154-159.
    PubMed     Abstract available


  311. ZHAO D, Mambetsariev I, Li H, Chen C, et al
    Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
    Lung Cancer. 2020;146:174-181.
    PubMed     Abstract available


  312. LAM ACL, Aggarwal R, Cheung S, Stewart EL, et al
    Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis.
    Lung Cancer. 2020;146:134-144.
    PubMed     Abstract available


  313. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed     Abstract available


  314. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed     Abstract available


  315. CHAN GH, Gwee YX, Low JL, Huang Y, et al
    Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
    Lung Cancer. 2020;146:145-153.
    PubMed     Abstract available


  316. MCFARLAND DC
    A comment on "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms".
    Lung Cancer. 2020 May 20. pii: S0169-5002(20)30429.
    PubMed    


  317. ZENKE Y, Niho S, Umemura S, Ishihara M, et al
    Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged >/=75 years with squamous-cell lung cancer: TORG1322.
    Lung Cancer. 2020;146:182-188.
    PubMed     Abstract available


  318. CRENGLE S
    Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
    Lung Cancer. 2020 May 16. pii: S0169-5002(20)30377.
    PubMed    


  319. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed     Abstract available


  320. ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
    A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
    Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.
    PubMed    


  321. SUN F, Franks K, Murray L, Lilley J, et al
    Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?
    Lung Cancer. 2020;146:1-5.
    PubMed     Abstract available


  322. MORGENSZTERN D, Johnson M, Rudin CM, Rossi M, et al
    SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
    Lung Cancer. 2020;145:126-131.
    PubMed     Abstract available


  323. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Lung Cancer. 2020;145:111-118.
    PubMed     Abstract available


  324. BEAGAN JJ, Bach S, van Boerdonk RA, van Dijk E, et al
    Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Lung Cancer. 2020;145:173-180.
    PubMed     Abstract available


  325. QUIST M, Langer SW, Lillelund C, Winther L, et al
    Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.
    Lung Cancer. 2020;145:76-82.
    PubMed     Abstract available


  326. DALL'OLIO FG, Maggio I, Massucci M, Mollica V, et al
    ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Lung Cancer. 2020;145:95-104.
    PubMed     Abstract available


  327. ROSSI D
    Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
    Lung Cancer. 2020;145:83-84.
    PubMed     Abstract available


  328. DREVET G, Duruisseaux M, Lafitte C, Derberne M, et al
    A reply to "A comment on "Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience".
    Lung Cancer. 2020 May 6. pii: S0169-5002(20)30406.
    PubMed    


  329. HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
    Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Lung Cancer. 2020;145:58-62.
    PubMed     Abstract available


  330. CHEN V, Iwama E, Kim IK, Giaccone G, et al
    Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
    Lung Cancer. 2020;145:48-57.
    PubMed     Abstract available


  331. TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
    Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Lung Cancer. 2020;145:18-26.
    PubMed     Abstract available


  332. SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
    A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
    Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.
    PubMed    


  333. HANDRA-LUCA A
    C-Myc in mucinous colloid carcinoma of the lung.
    Lung Cancer. 2020;143:93-94.
    PubMed    


  334. SMUK G, Pajor G, Szuhai K, Morreau H, et al
    Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Lung Cancer. 2020;143:80-85.
    PubMed     Abstract available


  335. OKUNO T, Arakawa S, Yoshida T, Ohe Y, et al
    Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Lung Cancer. 2020;143:95-96.
    PubMed    


  336. KNEUERTZ PJ, Carbone DP, D'Souza DM, Shilo K, et al
    Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Lung Cancer. 2020;143:60-66.
    PubMed     Abstract available


  337. ZHOU Y, Jiang W, Zeng L, Mi J, et al
    A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Lung Cancer. 2020;143:55-59.
    PubMed     Abstract available


  338. SHERMAN S, Rotem O, Shochat T, Zer A, et al
    Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Lung Cancer. 2020;143:40-46.
    PubMed     Abstract available


  339. TREJO BITTAR HE, Jerome JA, Hartman D, Pantanowitz L, et al
    Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
    Lung Cancer. 2020;143:12-18.
    PubMed     Abstract available


    April 2020
  340. LIN YT, Tsai TH, Wu SG, Liu YN, et al
    Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lung Cancer. 2020;145:1-9.
    PubMed     Abstract available


  341. THOMAS R, Chen YH, Hatabu H, Mak RH, et al
    Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.
    Lung Cancer. 2020;145:132-139.
    PubMed     Abstract available


  342. DENG J, Zhao M, Wang T, She Y, et al
    A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
    Lung Cancer. 2020;145:33-39.
    PubMed     Abstract available


  343. SOLOMON BJ, Kim EE, Winter M, Monti K, et al
    Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2020;145:167-172.
    PubMed     Abstract available


  344. SCHEFFLER M, Holzem A, Kron A, Nogova L, et al
    Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
    Lung Cancer. 2020;144:40-48.
    PubMed     Abstract available


  345. LIU B, Henschke CI, Flores RM, Taioli E, et al
    Serum cotinine verification of self-reported smoking status among adults eligible for lung cancer screening in the 1999-2018 National Health and Nutrition Examination Survey.
    Lung Cancer. 2020;144:49-56.
    PubMed     Abstract available


  346. POPAT S, Grohe C, Corral J, Reck M, et al
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Lung Cancer. 2020;144:76-84.
    PubMed     Abstract available


  347. DE RUITER JC, Heineman DJ, Daniels JM, van Diessen JN, et al
    The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
    Lung Cancer. 2020;144:64-70.
    PubMed     Abstract available


  348. BREADNER D, Blanchette P, Shanmuganathan S, Boldt RG, et al
    Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2020;144:57-63.
    PubMed     Abstract available


  349. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2020 Apr 18. pii: S0169-5002(20)30337.
    PubMed     Abstract available


  350. GOFFIN JR
    Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2020 Apr 4. pii: S0169-5002(20)30351.
    PubMed    


  351. ESCOIN-PEREZ C, Blasco S, Juan-Vidal O
    Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
    Lung Cancer. 2020;144:1-9.
    PubMed     Abstract available


  352. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services".
    Lung Cancer. 2020;142:140-141.
    PubMed    


  353. STIRLING R, Stenger M, Zalcberg J
    Comment on: 'Hospital lung surgery volume and patient outcomes'.
    Lung Cancer. 2020;142:138-139.
    PubMed    


  354. MOODLEY S, Lian EY, Crupi MJF, Hyndman BD, et al
    RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
    Lung Cancer. 2020;142:123-131.
    PubMed     Abstract available


  355. SALA L, Mancin M, Pastore A, Seminati D, et al
    Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
    Lung Cancer. 2020;142:120-122.
    PubMed     Abstract available


  356. CHEN HF, Wang WX, Xu CW, Huang LC, et al
    A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Lung Cancer. 2020;142:59-62.
    PubMed     Abstract available


  357. ZUCALI PA, Perrino M, De Vincenzo F, Giordano L, et al
    A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Lung Cancer. 2020;142:132-137.
    PubMed     Abstract available


  358. CHAN OSH, Lam KC, Li JYC, Choi FPT, et al
    ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Lung Cancer. 2020;142:41-46.
    PubMed     Abstract available


  359. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer(1).
    Lung Cancer. 2020;142:28-33.
    PubMed     Abstract available


  360. AN N, Leng X, Wang X, Sun Y, et al
    Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis.
    Lung Cancer. 2020;142:13-19.
    PubMed     Abstract available


    March 2020
  361. FRUH M, Panje CM, Reck M, Blackhall F, et al
    Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
    Lung Cancer. 2020;146:6-11.
    PubMed     Abstract available


  362. VERONESI G, Navone N, Novellis P, Dieci E, et al
    Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Lung Cancer. 2020;143:73-79.
    PubMed     Abstract available


  363. BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Lung Cancer. 2020;143:67-72.
    PubMed     Abstract available


  364. KARAYAMA M, Yoshizawa N, Sugiyama M, Mori K, et al
    Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2020;143:47-54.
    PubMed     Abstract available


  365. MA L, Zhang Q, Dong Y, Li H, et al
    SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.
    PubMed    


  366. YANG G, Li J, Xu H, Yang Y, et al
    EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30344.
    PubMed     Abstract available


  367. SANCHIS-BORJA M, Ricordel C, Chiappa AM, Hureaux J, et al
    Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
    Lung Cancer. 2020;143:36-39.
    PubMed     Abstract available


  368. EIDE IJZ, Helland A, Ekman S, Mellemgaard A, et al
    Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Lung Cancer. 2020;143:27-35.
    PubMed     Abstract available


  369. PETERS S, Shaw AT, Besse B, Felip E, et al
    Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
    Lung Cancer. 2020;144:10-19.
    PubMed     Abstract available


  370. SHEINSON D, Wong WB, Wu N, Mansfield AS, et al
    Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2020;143:86-92.
    PubMed     Abstract available


  371. ROCH B, Coffy A, Jean-Baptiste S, Palaysi E, et al
    Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Lung Cancer. 2020;143:19-26.
    PubMed     Abstract available


  372. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed     Abstract available


  373. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed     Abstract available


  374. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed     Abstract available


  375. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed     Abstract available


    February 2020
  376. TANG Y, Xia B, Xie R, Xu X, et al
    Erratum to "Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI" [Lung Cancer, 140 (February) (2020) 65-70].
    Lung Cancer. 2020 Feb 27. pii: S0169-5002(20)30278.
    PubMed    


  377. KHORRAMI M, Bera K, Leo P, Vaidya P, et al
    Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study.
    Lung Cancer. 2020;142:90-97.
    PubMed     Abstract available


  378. HIRPARA DH, Gupta V, Davis LE, Zhao H, et al
    Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes.
    Lung Cancer. 2020;142:80-89.
    PubMed     Abstract available


  379. CORRAO G, Marvaso G, Ferrara R, Lo Russo G, et al
    Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
    Lung Cancer. 2020;142:70-79.
    PubMed     Abstract available


  380. THEELEN WS, de Jong MC, Baas P
    Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
    Lung Cancer. 2020;142:106-113.
    PubMed     Abstract available


  381. PERTEJO-FERNANDEZ A, Ricciuti B, Hammond SP, Marty FM, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Lung Cancer. 2020 Feb 24. pii: S0169-5002(20)30310.
    PubMed     Abstract available


  382. CHEN K, Cheng G, Zhang F, Zhu G, et al
    PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Lung Cancer. 2020;142:98-105.
    PubMed     Abstract available


  383. BESSE B, Garrido P, Cortot AB, Johnson M, et al
    Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Lung Cancer. 2020;142:63-69.
    PubMed     Abstract available


  384. BOUSEMA JE, Heineman DJ, Dijkgraaf MGW, Annema JT, et al
    Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery.
    Lung Cancer. 2020;142:51-58.
    PubMed     Abstract available


  385. FINKE I, Behrens G, Schwettmann L, Gerken M, et al
    Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration.
    Lung Cancer. 2020;142:1-8.
    PubMed     Abstract available


  386. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.
    PubMed    


  387. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed     Abstract available


  388. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed     Abstract available


  389. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed     Abstract available


  390. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed     Abstract available


  391. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed     Abstract available


  392. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed     Abstract available


  393. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.
    PubMed    


  394. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.
    PubMed    


    January 2020
  395. ALEXANDER M, Pavlakis N, John T, O'Connell R, et al
    A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Lung Cancer. 2020;142:34-40.
    PubMed     Abstract available


  396. ZHUANG H, Jiang W, Cheng W, Qian K, et al
    Corrigendum to "Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis" [Lung Cancer 68 (1) (2010) 27-38].
    Lung Cancer. 2020 Jan 16. pii: S0169-5002(20)30003.
    PubMed    


  397. WOLFF HB, Alberts L, van der Linden N, Bongers ML, et al
    Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
    Lung Cancer. 2020;141:89-96.
    PubMed     Abstract available


  398. JOHNSON AM, Johnson A, Hines RB, Mohammadi R, et al
    Neighborhood context and non-small cell lung cancer outcomes in Florida non-elderly patients by race/ethnicity.
    Lung Cancer. 2020;142:20-27.
    PubMed     Abstract available


  399. RICE SJ, Liu X, Hyland V, Liu Z, et al
    Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Lung Cancer. 2020;141:97-100.
    PubMed     Abstract available


  400. ZENG L, Xiao L, Jiang W, Yang H, et al
    Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Lung Cancer. 2020;141:82-88.
    PubMed     Abstract available


  401. SERRA P, Centeno C, Sanz-Santos J, Torky M, et al
    Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?
    Lung Cancer. 2020;142:9-12.
    PubMed     Abstract available


  402. JONES GS, Elimian K, Baldwin DR, Hubbard RB, et al
    A systematic review of survival following anti-cancer treatment for small cell lung cancer.
    Lung Cancer. 2020;141:44-55.
    PubMed     Abstract available


  403. NIHO S, Yoshida T, Akimoto T, Sakamaki K, et al
    Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Lung Cancer. 2020;141:64-71.
    PubMed     Abstract available


  404. YOSHIMURA K, Inoue Y, Tsuchiya K, Karayama M, et al
    Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Lung Cancer. 2020;141:21-31.
    PubMed     Abstract available


  405. NAGASAKA M, Lehman A, Chlebowski R, Haynes BM, et al
    COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report.
    Lung Cancer. 2020;141:78-81.
    PubMed     Abstract available


  406. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.
    Lung Cancer. 2020;141:56-63.
    PubMed     Abstract available


  407. CAO X, Ganti AK, Stinchcombe T, Wong ML, et al
    Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
    Lung Cancer. 2020;141:14-20.
    PubMed     Abstract available


  408. BUGLIONE M, Jereczek-Fossa BA, Bonu ML, Franceschini D, et al
    Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Lung Cancer. 2020;141:1-8.
    PubMed     Abstract available


  409. ZHOU F, Zhao W, Chen X, Zhang J, et al
    Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation.
    Lung Cancer. 2020;139:219-220.
    PubMed    


  410. ZELTSMAN M, Dozier J, Vaghjiani RG, Poch A, et al
    Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.
    Lung Cancer. 2020;139:68-72.
    PubMed     Abstract available


  411. PINSKY P, Gierada DS
    Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans.
    Lung Cancer. 2020;139:179-184.
    PubMed     Abstract available


  412. MIYAKE N, Ochi N, Yamane H, Fukazawa T, et al
    Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
    Lung Cancer. 2020;139:170-178.
    PubMed     Abstract available


  413. WIESWEG M, Herold T, Metzenmacher M, Eberhardt WE, et al
    Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
    Lung Cancer. 2020;139:165-168.
    PubMed     Abstract available


  414. YANG S, Mao S, Li X, Zhao C, et al
    Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Lung Cancer. 2020;139:133-139.
    PubMed     Abstract available


  415. STOCKHAMMER P, Ploenes T, Theegarten D, Schuler M, et al
    Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Lung Cancer. 2020;139:124-132.
    PubMed     Abstract available


  416. ZHANG JT, Li Y, Yan LX, Zhu ZF, et al
    Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Lung Cancer. 2020;139:118-123.
    PubMed     Abstract available


  417. WANG B, Tang Y, Chen Y, Hamal P, et al
    Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules.
    Lung Cancer. 2020;139:103-110.
    PubMed     Abstract available


  418. CHEN X, Pang Z, Wang Y, Bie F, et al
    The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database.
    Lung Cancer. 2020;139:94-102.
    PubMed     Abstract available


  419. SOUSA AC, Silveira C, Janeiro A, Malveiro S, et al
    Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Lung Cancer. 2020;139:35-40.
    PubMed     Abstract available


  420. CARACENI A, Lo Dico S, Zecca E, Brunelli C, et al
    Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
    Lung Cancer. 2020;139:13-17.
    PubMed     Abstract available


  421. RIBEIRO MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, et al
    Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Lung Cancer. 2020;139:9-12.
    PubMed     Abstract available


    December 2019
  422. GIAJ LEVRA M, Cotte FE, Corre R, Calvet C, et al
    Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Lung Cancer. 2019;140:99-106.
    PubMed     Abstract available


  423. EBERT EBF, McCulloch T, Hansen KH, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Lung Cancer. 2019;141:37-43.
    PubMed     Abstract available


  424. SMIT HJM, Aerts J, van den Heuvel M, Hiltermann TJN, et al
    Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Lung Cancer. 2019;140:107-112.
    PubMed     Abstract available


  425. VAN VEGGEL B, Madeira R Santos JFV, Hashemi SMS, Paats MS, et al
    Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    Lung Cancer. 2019;141:9-13.
    PubMed     Abstract available


  426. TOFFART AC, Asfari S, Mc Leer A, Reymond E, et al
    Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing.
    Lung Cancer. 2019;140:93-98.
    PubMed     Abstract available


  427. TANG Y, Xia B, Xu X, Zhang M, et al
    Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.
    Lung Cancer. 2019;140:65-70.
    PubMed     Abstract available


  428. NACHIRA D, Meacci E, Congedo MT, Chiappetta M, et al
    Upstaging, centrality and survival in early stage non-small cell lung cancer video-assisted surgery: Lymph nodal upstaging in lung cancer surgery: is it really a surgical technique problem?
    Lung Cancer. 2019 Dec 18. pii: S0169-5002(19)30774.
    PubMed    


  429. GROSU HB, Manzanera A, Shivakumar S, Sun S, et al
    Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
    Lung Cancer. 2019;140:55-58.
    PubMed     Abstract available


  430. HELMINEN O, Valo J, Andersen H, Lautamaki A, et al
    Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.
    Lung Cancer. 2019;140:1-7.
    PubMed     Abstract available


    November 2019
  431. KUBOTA K, Kunitoh H, Seto T, Shimada N, et al
    Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
    Lung Cancer. 2019;141:32-36.
    PubMed     Abstract available


  432. BLOM EF, Ten Haaf K, de Koning HJ
    Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
    Lung Cancer. 2019;139:200-206.
    PubMed     Abstract available


  433. NAKAGAWA K, Hida T, Nokihara H, Morise M, et al
    Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;139:195-199.
    PubMed     Abstract available


  434. NARTEY Y, Stewart I, Khakwani A, Beattie V, et al
    Is the English Cancer Patient Experience Survey representative? A comparative analysis with the National Lung Cancer Audit.
    Lung Cancer. 2019;140:27-34.
    PubMed     Abstract available


  435. SHIN SH, Jeong BH, Jhun BW, Yoo H, et al
    The utility of endosonography for mediastinal staging of non-small cell lung cancer in patients with radiological N0 disease.
    Lung Cancer. 2019;139:151-156.
    PubMed     Abstract available


  436. TAN AC, Lai GGY, Tan GS, Poon SY, et al
    Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Lung Cancer. 2019;139:207-215.
    PubMed     Abstract available


  437. HASHIMOTO K, Kaira K, Kawasaki T, Yamaguchi O, et al
    Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
    Lung Cancer. 2019 Nov 25. pii: S0169-5002(19)30744.
    PubMed    


  438. ANDERSEN BL, Valentine TR, Lo SB, Carbone DP, et al
    Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms.
    Lung Cancer. 2019 Nov 21. pii: S0169-5002(19)30729.
    PubMed     Abstract available


  439. MORITA R, Okishio K, Shimizu J, Saito H, et al
    Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Lung Cancer. 2019;140:8-18.
    PubMed     Abstract available


  440. ICHIHARA E, Harada D, Inoue K, Sato K, et al
    The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
    Lung Cancer. 2019;139:140-145.
    PubMed     Abstract available


  441. PRUIS MA, Geurts-Giele WRR, von der TJH, Meijssen IC, et al
    Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Lung Cancer. 2019;140:46-54.
    PubMed     Abstract available


  442. BEAU-FALLER M, Pencreach E, Leduc C, Blons H, et al
    Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the
    Lung Cancer. 2019;140:19-26.
    PubMed     Abstract available


  443. TENDLER S, Holmqvist M, Wagenius G, Lewensohn R, et al
    Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.
    Lung Cancer. 2019;139:111-117.
    PubMed     Abstract available


  444. GIAJ-LEVRA N, Giaj Levra M, Berghmans T, Novello S, et al
    Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
    Lung Cancer. 2019 Nov 13. pii: S0169-5002(19)30719.
    PubMed    


  445. CONG M, Feng H, Ren JL, Xu Q, et al
    Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
    Lung Cancer. 2019;139:73-79.
    PubMed     Abstract available


  446. LI T, Zhang F, Wu Z, Cui L, et al
    PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
    Lung Cancer. 2019;139:146-150.
    PubMed     Abstract available


  447. GERBER DE, Camidge DR, Morgensztern D, Cetnar J, et al
    Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
    Lung Cancer. 2019;139:60-67.
    PubMed     Abstract available


  448. TAKEDA M, Sakai K, Hayashi H, Tanaka K, et al
    Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Lung Cancer. 2019;139:28-34.
    PubMed     Abstract available


  449. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].
    Lung Cancer. 2019 Nov 2. pii: S0169-5002(19)30677.
    PubMed    


  450. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2019;139:80-88.
    PubMed     Abstract available


  451. BALATA H, Traverse-Healy L, Blandin-Knight S, Armitage C, et al
    Attending community-based lung cancer screening influences smoking behaviour in deprived populations.
    Lung Cancer. 2019;139:41-46.
    PubMed     Abstract available


    October 2019
  452. REALE ML, De Luca E, Lombardi P, Marandino L, et al
    Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
    Lung Cancer. 2019;139:47-54.
    PubMed     Abstract available


  453. ZHANG D, Zhang Y, Huang Y, Kong L, et al
    Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
    Lung Cancer. 2019;139:18-21.
    PubMed     Abstract available


  454. DREVET G, Duruisseaux M, Maury JM, Benjamin R, et al
    Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience.
    Lung Cancer. 2019;139:55-59.
    PubMed     Abstract available


  455. KATAOKA Y, Yamamoto Y, Otsuki T, Kaku S, et al
    Corrigendum to "External validation of prognostic indices for overall survival of malignant pleural mesothelioma" [Lung Cancer 113 (November) (2017) 88-92].
    Lung Cancer. 2019 Oct 23. pii: S0169-5002(19)30678.
    PubMed    


  456. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2019;139:185-194.
    PubMed     Abstract available


  457. EICHHORN F, Klotz LV, Muley T, Kobinger S, et al
    Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.
    Lung Cancer. 2019;138:95-101.
    PubMed     Abstract available


  458. THOMPSON JC, Hwang WT, Davis C, Deshpande C, et al
    Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Lung Cancer. 2019;139:1-8.
    PubMed     Abstract available


  459. TSUKITA Y, Inoue A, Sugawara S, Kuyama S, et al
    Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Lung Cancer. 2019;139:89-93.
    PubMed     Abstract available


  460. SHE L, Hu H, Liao M, Xia X, et al
    Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    Lung Cancer. 2019;138:88-94.
    PubMed     Abstract available


  461. PULITI D, Mascalchi M, Carozzi FM, Carrozzi L, et al
    Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.
    Lung Cancer. 2019;138:72-78.
    PubMed     Abstract available


  462. OU SI, Gadgeel SM, Barlesi F, Yang JC, et al
    Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;139:22-27.
    PubMed     Abstract available


  463. NAITO T, Udagawa H, Umemura S, Sakai T, et al
    Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Lung Cancer. 2019;138:35-42.
    PubMed     Abstract available


  464. PEROL M, Pavlakis N, Levchenko E, Platania M, et al
    Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;138:79-87.
    PubMed     Abstract available


  465. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9].
    Lung Cancer. 2019;136:156.
    PubMed    


  466. BAR J, Ofek E, Barshack I, Gottfried T, et al
    Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Lung Cancer. 2019;138:109-115.
    PubMed     Abstract available


    September 2019
  467. ASAHINA H, Oizumi S, Takamura K, Harada T, et al
    A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Lung Cancer. 2019;138:65-71.
    PubMed     Abstract available


  468. MEHLMAN C, Cadranel J, Rousseau-Bussac G, Lacave R, et al
    Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
    Lung Cancer. 2019;137:149-156.
    PubMed     Abstract available


  469. STAMATIS G, Leschber G, Schwarz B, Brintrup DL, et al
    Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2cm, stage IA (7th edition of TNM staging
    Lung Cancer. 2019;138:19-26.
    PubMed     Abstract available


  470. PARK SY, Byun GE, Lee CY, Lee JG, et al
    Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
    Lung Cancer. 2019;138:1-5.
    PubMed     Abstract available


  471. GELATTI ACZ, Drilon A, Santini FC
    Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;137:113-122.
    PubMed     Abstract available


  472. TERAMOTO K, Igarashi T, Kataoka Y, Ishida M, et al
    Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Lung Cancer. 2019;137:56-63.
    PubMed     Abstract available


  473. YOSHIMURA A, Yamada T, Miyagawa-Hayashino A, Sonobe Y, et al
    Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
    Lung Cancer. 2019;137:108-112.
    PubMed     Abstract available


  474. AGER BJ, Wells SM, Gruhl JD, Stoddard GJ, et al
    Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Lung Cancer. 2019;138:6-12.
    PubMed     Abstract available


  475. KADOURI L, Rottenberg Y, Zick A, Hamburger T, et al
    Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Lung Cancer. 2019;137:48-51.
    PubMed     Abstract available


  476. GALLI G, De Toma A, Pagani F, Randon G, et al
    Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Lung Cancer. 2019;137:38-42.
    PubMed     Abstract available


  477. GUIBERT N, Jones G, Beeler JF, Plagnol V, et al
    Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2019;137:1-6.
    PubMed     Abstract available


  478. BODOR JN, Feliciano JL, Edelman MJ
    Corrigendum to "Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation" [Lung Cancer 135 (September) (2019) 16-20].
    Lung Cancer. 2019 Sep 5. pii: S0169-5002(19)30616.
    PubMed    


  479. LAN S, Li H, Liu Y, Ma L, et al
    Erratum to "Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer" [Lung Cancer 132 (June) (2019) 154-156].
    Lung Cancer. 2019 Sep 4. pii: S0169-5002(19)30622.
    PubMed    


  480. BESSE B, Barlesi F, Demedts I, Fuentes Pradera J, et al
    A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
    Lung Cancer. 2019;137:136-143.
    PubMed     Abstract available


  481. FRASER I, Lefresne S, Regan J, Berthelet E, et al
    Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis.
    Lung Cancer. 2019;135:97-103.
    PubMed     Abstract available


  482. HOJBJERG JA, Ebert EBF, Clement MS, Winther-Larsen A, et al
    Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
    Lung Cancer. 2019;135:92-96.
    PubMed     Abstract available


  483. CAPIZZI E, Dall'Olio FG, Gruppioni E, Sperandi F, et al
    Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Lung Cancer. 2019;135:88-91.
    PubMed     Abstract available


  484. HOPKINS RJ, Ko J, Gamble GD, Young RP, et al
    Airflow limitation and survival after surgery for non-small cell lung cancer: Results from a systematic review and lung cancer screening trial (NLST-ACRIN sub-study).
    Lung Cancer. 2019;135:80-87.
    PubMed     Abstract available


  485. KIM DW, Lee DH, Han JY, Lee J, et al
    Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Lung Cancer. 2019;135:66-72.
    PubMed     Abstract available


  486. GUO J, Wang X, Wang Y, Wang L, et al
    A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
    Lung Cancer. 2019;135:47-55.
    PubMed     Abstract available


  487. MESSARITAKIS I, Nikolaou M, Koinis F, Politaki E, et al
    Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Lung Cancer. 2019;135:33-39.
    PubMed     Abstract available


  488. CADHAM CJ, Jayasekera JC, Advani SM, Fallon SJ, et al
    Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.
    Lung Cancer. 2019;135:205-216.
    PubMed     Abstract available


  489. GRIESINGER F, Korol EE, Kayaniyil S, Varol N, et al
    Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Lung Cancer. 2019;135:196-204.
    PubMed     Abstract available


  490. NOSAKI K, Saka H, Hosomi Y, Baas P, et al
    Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Lung Cancer. 2019;135:188-195.
    PubMed     Abstract available


  491. HEINEMAN DJ, Hoeijmakers F, Beck N, Dickhoff C, et al
    Impact of health care organization on surgical lung cancer care.
    Lung Cancer. 2019;135:181-187.
    PubMed     Abstract available


  492. YOKOYAMA T, Yoshioka H, Fujimoto D, Demura Y, et al
    A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Lung Cancer. 2019;135:175-180.
    PubMed     Abstract available


  493. ISLA D, De Las Penas R, Insa A, Marse R, et al
    Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
    Lung Cancer. 2019;135:161-168.
    PubMed     Abstract available


  494. BODOR JN, Feliciano JL, Edelman MJ
    Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation.
    Lung Cancer. 2019;135:16-20.
    PubMed     Abstract available


  495. ALCARAZ J, Carrasco JL, Millares L, Luis IC, et al
    Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.
    Lung Cancer. 2019;135:151-160.
    PubMed     Abstract available


  496. UDAGAWA H, Akamatsu H, Tanaka K, Takeda M, et al
    Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    Lung Cancer. 2019;135:145-150.
    PubMed     Abstract available


  497. ZHANG L, Pu D, Liu D, Wang Y, et al
    Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
    Lung Cancer. 2019;135:130-137.
    PubMed     Abstract available


  498. RUDNICKA J, Kowalkowski T, Buszewski B
    Searching for selected VOCs in human breath samples as potential markers of lung cancer.
    Lung Cancer. 2019;135:123-129.
    PubMed     Abstract available


  499. NOOR ZS, Goldman JW, Lawler WE, Telivala B, et al
    Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;135:104-109.
    PubMed     Abstract available


  500. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
    Lung Cancer. 2019;135:1-9.
    PubMed     Abstract available


    August 2019
  501. SUMITOMO R, Hirai T, Fujita M, Murakami H, et al
    PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;136:136-144.
    PubMed     Abstract available


  502. KIM YJ, Keam B, Ock CY, Song S, et al
    A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Lung Cancer. 2019;136:122-128.
    PubMed     Abstract available


  503. BHANDARI S, Tripathi P, Pham D, Pinkston C, et al
    Performance of community-based lung cancer screening program in a Histoplasma endemic region.
    Lung Cancer. 2019;136:102-104.
    PubMed     Abstract available


  504. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
    Lung Cancer. 2019 Aug 26. pii: S0169-5002(19)30621.
    PubMed    


  505. ZHOU K, Jiang C, Li Q
    Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
    Lung Cancer. 2019;136:98-101.
    PubMed     Abstract available


  506. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].
    Lung Cancer. 2019 Aug 24. pii: S0169-5002(19)30617.
    PubMed    


  507. YOON DW, Shin DW, Cho JH, Yang JH, et al
    Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients.
    Lung Cancer. 2019;136:115-121.
    PubMed     Abstract available


  508. OU SI, Cui J, Schrock AB, Goldberg ME, et al
    Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-
    Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614.
    PubMed    


  509. TAY RY, Heigener D, Reck M, Califano R, et al
    Immune checkpoint blockade in small cell lung cancer.
    Lung Cancer. 2019;137:31-37.
    PubMed     Abstract available


  510. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
    Lung Cancer. 2019 Aug 21. pii: S0169-5002(19)30618.
    PubMed    


  511. JIN J, Gan Y, Liu H, Wang Z, et al
    Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation.
    Lung Cancer. 2019;136:129-135.
    PubMed     Abstract available


  512. HE Y, Jia K, Dziadziuszko R, Zhao S, et al
    Galectin-9 in non-small cell lung cancer.
    Lung Cancer. 2019;136:80-85.
    PubMed     Abstract available


  513. SHOJI F, Takeoka H, Kozuma Y, Toyokawa G, et al
    Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2019;136:45-51.
    PubMed     Abstract available


  514. GAUVAIN C, Vauleon E, Chouaid C, Le Rhun E, et al
    Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].
    Lung Cancer. 2019 Aug 14. pii: S0169-5002(18)30595.
    PubMed    


  515. MORGENSZTERN D, Karaseva N, Felip E, Delgado I, et al
    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
    Lung Cancer. 2019;136:74-79.
    PubMed     Abstract available


  516. VILLARUZ LC, Cobo M, Syrigos K, Mavroudis D, et al
    A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Lung Cancer. 2019;136:52-56.
    PubMed     Abstract available


  517. DESCOURT R, Perol M, Rousseau-Bussac G, Planchard D, et al
    Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Lung Cancer. 2019;136:109-114.
    PubMed     Abstract available


  518. LEE GJ, Lee H, Woo IS, Kim T, et al
    Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16].
    Lung Cancer. 2019 Aug 13. pii: S0169-5002(19)30554.
    PubMed    


  519. LEVY A, Hendriks LEL, Le Pechoux C, Falk S, et al
    Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.
    Lung Cancer. 2019;136:145-147.
    PubMed     Abstract available


  520. MURTHY V, Katzman DP, Tsay JJ, Bessich JL, et al
    Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
    Lung Cancer. 2019;137:94-99.
    PubMed     Abstract available


  521. WEN J, Chen J, Fan M
    Comment on the article titled "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
    Lung Cancer. 2019 Aug 12. pii: S0169-5002(19)30568.
    PubMed    


  522. RAJADURAI P, Cheah PL, How SH, Liam CK, et al
    Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
    Lung Cancer. 2019;136:65-73.
    PubMed     Abstract available


  523. CHENG H, Li XJ, Wang XJ, Chen ZW, et al
    A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;137:7-13.
    PubMed     Abstract available


  524. MAISONNEUVE P, Iavicoli S, Veronesi G
    Response to comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Aug 4. pii: S0169-5002(19)30574.
    PubMed    


  525. TANG W, Li X, Xie X, Sun X, et al
    EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2019;136:6-14.
    PubMed     Abstract available


  526. HARAGAN A, Field JK, Davies MPA, Escriu C, et al
    Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
    Lung Cancer. 2019;134:79-84.
    PubMed     Abstract available


  527. ZUGAZAGOITIA J, Gomez-Rueda A, Jantus-Lewintre E, Isla D, et al
    Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Lung Cancer. 2019;134:72-78.
    PubMed     Abstract available


  528. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
    Lung Cancer. 2019;134:66-71.
    PubMed     Abstract available


  529. BOUSEMA JE, van Dorp M, Hoeijmakers F, Huijbregts IA, et al
    Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis.
    Lung Cancer. 2019;134:52-58.
    PubMed     Abstract available


  530. HELLYER JA, Stehr H, Das M, Padda SK, et al
    Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Lung Cancer. 2019;134:42-45.
    PubMed     Abstract available


  531. VAN DE VEN M, Retel VP, Koffijberg H, van Harten WH, et al
    Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
    Lung Cancer. 2019;134:34-41.
    PubMed     Abstract available


  532. MELOSKY B, Juergens R, McLeod D, Leighl N, et al
    Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2019;134:259-267.
    PubMed     Abstract available


  533. BOADA M, Guzman R, Montesinos M, Libreros A, et al
    UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
    Lung Cancer. 2019;134:254-258.
    PubMed     Abstract available


  534. BALATA H, Evison M, Sharman A, Crosbie P, et al
    CT screening for lung cancer: Are we ready to implement in Europe?
    Lung Cancer. 2019;134:25-33.
    PubMed     Abstract available


  535. ACKERMANN CJ, Reck M, Paz-Ares L, Barlesi F, et al
    First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Lung Cancer. 2019;134:245-253.
    PubMed     Abstract available


  536. VANNITAMBY A, Hendry S, Irving L, Steinfort D, et al
    Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Lung Cancer. 2019;134:233-237.
    PubMed     Abstract available


  537. FRANCAVIGLIA I, Magliacane G, Lazzari C, Grassini G, et al
    Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Lung Cancer. 2019;134:225-232.
    PubMed     Abstract available


  538. LIU Z, Liang H, Lin J, Cai X, et al
    The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
    Lung Cancer. 2019;134:218-224.
    PubMed     Abstract available


  539. CAPELLETTO E, Migliorino MR, Morabito A, Chiari R, et al
    Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
    Lung Cancer. 2019;134:210-217.
    PubMed     Abstract available


  540. YOSHIMURA K, Inoue Y, Karayama M, Tsuchiya K, et al
    Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Lung Cancer. 2019;134:202-209.
    PubMed     Abstract available


  541. DING PN, Becker TM, Bray VJ, Chua W, et al
    The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Lung Cancer. 2019;134:187-193.
    PubMed     Abstract available


  542. KASAHARA N, Kaira K, Yamaguchi K, Masubuchi H, et al
    Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
    Lung Cancer. 2019;134:180-186.
    PubMed     Abstract available


  543. DIETEL M, Savelov N, Salanova R, Micke P, et al
    Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Lung Cancer. 2019;134:174-179.
    PubMed     Abstract available


  544. OWEN DH, Williams TM, Bertino EM, Mo X, et al
    Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Lung Cancer. 2019;134:167-173.
    PubMed     Abstract available


  545. TAN KS
    Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.
    Lung Cancer. 2019;134:16-24.
    PubMed     Abstract available


  546. HYUN MH, Lee ES, Eo JS, Kim S, et al
    Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
    Lung Cancer. 2019;134:158-166.
    PubMed     Abstract available


  547. KIM H, Goo JM, Paeng JC, Kim YT, et al
    Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification.
    Lung Cancer. 2019;134:151-157.
    PubMed     Abstract available


  548. MANJUNATH Y, Upparahalli SV, Suvilesh KN, Avella DM, et al
    Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Lung Cancer. 2019;134:147-150.
    PubMed     Abstract available


  549. GIBSON AJW, Li H, D'Silva A, Elegbede AA, et al
    Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Lung Cancer. 2019;134:141-146.
    PubMed     Abstract available


  550. DAFNI U, Tsourti Z, Vervita K, Peters S, et al
    Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Lung Cancer. 2019;134:127-140.
    PubMed     Abstract available


  551. SANTO A, Pilotto S, Galetta D, Grossi F, et al
    Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
    Lung Cancer. 2019;134:121-126.
    PubMed     Abstract available


  552. ZHANG B, Niu X, Zhang Q, Wang C, et al
    Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Lung Cancer. 2019;134:108-116.
    PubMed     Abstract available


  553. NAKAMURA H, Sugano M, Miyashita T, Hashimoto H, et al
    Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.
    Lung Cancer. 2019;134:100-107.
    PubMed     Abstract available


  554. HAYASHI H, Iihara H, Hirose C, Fukuda Y, et al
    Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Lung Cancer. 2019;134:1-6.
    PubMed     Abstract available


  555. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30].
    Lung Cancer. 2019;134:279.
    PubMed    


  556. CHOE EA, Cha YJ, Kim JH, Pyo KH, et al
    Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Lung Cancer. 2019;136:30-36.
    PubMed     Abstract available


  557. WANG G, Ionescu DN, Lee CH, Hiruki T, et al
    PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
    Lung Cancer. 2019;136:1-5.
    PubMed     Abstract available


    July 2019
  558. GRONDAHL V, Binderup T, Langer SW, Petersen RH, et al
    Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149].
    Lung Cancer. 2019 Jul 31. pii: S0169-5002(19)30561.
    PubMed    


  559. BARBONE F, Barbiero F, Fasola G
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Jul 27. pii: S0169-5002(19)30564.
    PubMed    


  560. WANG X, Leader JK, Wang R, Wilson D, et al
    Erratum to "Vasculature surrounding a nodule: A novel lung cancer biomarker" [Lung Cancer 114 (December) (2017) 38-43].
    Lung Cancer. 2019 Jul 26. pii: S0169-5002(19)30560.
    PubMed    


  561. SUBRAMANIAN J, Fernandes AW, Laliberte F, Pavilack M, et al
    The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung Cancer. 2019;138:131-138.
    PubMed     Abstract available


  562. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
    Lung Cancer. 2019 Jul 22. pii: S0169-5002(19)30555.
    PubMed    


  563. AWAD MM, Leonardi GC, Kravets S, Dahlberg SE, et al
    Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Lung Cancer. 2019;133:96-102.
    PubMed     Abstract available


  564. PETERS S, Felip E, Dafni U, Belka C, et al
    Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Lung Cancer. 2019;133:83-87.
    PubMed     Abstract available


  565. LI X, Zhang C, Sun Z, Yang F, et al
    Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Lung Cancer. 2019;133:75-82.
    PubMed     Abstract available


  566. TSAKONAS G, Botling J, Micke P, Rivard C, et al
    c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
    Lung Cancer. 2019;133:69-74.
    PubMed     Abstract available


  567. MORABITO A, Piccirillo MC, Maione P, Luciani A, et al
    Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
    Lung Cancer. 2019;133:62-68.
    PubMed     Abstract available


  568. DIMOU A, Bamias A, Gogas H, Syrigos K, et al
    Inhibition of the Hedgehog pathway in lung cancer.
    Lung Cancer. 2019;133:56-61.
    PubMed     Abstract available


  569. MELOSKY B, Bradbury P, Tu D, Florescu M, et al
    Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group
    Lung Cancer. 2019;133:48-55.
    PubMed     Abstract available


  570. SAKIN A, Sahin S, Yasar N, Demir C, et al
    Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
    Lung Cancer. 2019;133:38-44.
    PubMed     Abstract available


  571. LOWENSTEIN M, Vijayaraghavan M, Burke NJ, Karliner L, et al
    Real-world lung cancer screening decision-making: Barriers and facilitators.
    Lung Cancer. 2019;133:32-37.
    PubMed     Abstract available


  572. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Lung Cancer. 2019;133:144-150.
    PubMed     Abstract available


  573. SHINDE A, Horne ZD, Li R, Glaser S, et al
    Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Lung Cancer. 2019;133:136-143.
    PubMed     Abstract available


  574. DEGENS JHRJ, Sanders KJC, de Jong EEC, Groen HJM, et al
    The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
    Lung Cancer. 2019;133:130-135.
    PubMed     Abstract available


  575. ROMERO-VIELVA L, Viteri S, Moya-Horno I, Toscas JI, et al
    Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Lung Cancer. 2019;133:117-122.
    PubMed     Abstract available


  576. KSIENSKI D, Wai ES, Croteau N, Freeman AT, et al
    Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Lung Cancer. 2019;133:110-116.
    PubMed     Abstract available


  577. GAYE E, Geier M, Bore P, Guilloique M, et al
    Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Lung Cancer. 2019;133:1-3.
    PubMed     Abstract available


    June 2019
  578. PARDO-CABELLO AJ, Manzano-Gamero V
    Small cell lung cancer elevates procalcitonin levels in the absence of infection.
    Lung Cancer. 2019 Jun 17. pii: S0169-5002(19)30511.
    PubMed    


  579. FUJIMOTO D, Yomota M, Sekine A, Morita M, et al
    Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494.
    PubMed     Abstract available


  580. YOO JK, Lee JM, Kang SH, Jeon SH, et al
    The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP.
    Lung Cancer. 2019;132:99-106.
    PubMed     Abstract available


  581. SUH CH, Kim KW, Pyo J, Hatabu H, et al
    The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
    Lung Cancer. 2019;132:79-86.
    PubMed     Abstract available


  582. GALLI G, Triulzi T, Proto C, Signorelli D, et al
    Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Lung Cancer. 2019;132:72-78.
    PubMed     Abstract available


  583. ASSOUN S, Theou-Anton N, Nguenang M, Cazes A, et al
    Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;132:65-71.
    PubMed     Abstract available


  584. ICHIHARA E, Hotta K, Ninomiya K, Kubo T, et al
    Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Lung Cancer. 2019;132:54-58.
    PubMed     Abstract available


  585. CUI S, Ni Y, Zhao Y, Li Z, et al
    Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Lung Cancer. 2019;132:45-53.
    PubMed     Abstract available


  586. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Lung Cancer. 2019;132:36-38.
    PubMed     Abstract available


  587. PLATANIA M, Pasini F, Porcu L, Boeri M, et al
    Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Lung Cancer. 2019;132:17-23.
    PubMed     Abstract available


  588. VAD-NIELSEN J, Gammelgaard KR, Daugaard TF, Nielsen AL, et al
    Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Lung Cancer. 2019;132:132-140.
    PubMed     Abstract available


  589. PARK K, Bennouna J, Boyer M, Hida T, et al
    Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2019;132:126-131.
    PubMed     Abstract available


  590. MINNITI G, Scaringi C, Lanzetta G, Anzellini D, et al
    Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2019;132:119-125.
    PubMed     Abstract available


  591. LIANG F, Wu C, Gu H, Zhu M, et al
    Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening.
    Lung Cancer. 2019;132:114-118.
    PubMed     Abstract available


  592. OYANAGI J, Koh Y, Sato K, Mori K, et al
    Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2019;132:107-113.
    PubMed     Abstract available


  593. FUKUDA M, Kitazaki T, Ogawara D, Ichiki M, et al
    Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Lung Cancer. 2019;132:1-8.
    PubMed     Abstract available


  594. SONG T, Jiang L, Lin Y
    Comment on: 'Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas'.
    Lung Cancer. 2019;132:150.
    PubMed    


  595. HSIEH MS, Lin MW
    Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas."
    Lung Cancer. 2019;132:151.
    PubMed    


    May 2019
  596. TAKANO N, Ariyasu R, Koyama J, Sonoda T, et al
    Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
    Lung Cancer. 2019;131:69-77.
    PubMed     Abstract available


  597. LIN C, Shi X, Yang S, Zhao J, et al
    Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:62-68.
    PubMed     Abstract available


  598. PEROL M, Winfree KB, Cuyun Carter G, Lin Cui Z, et al
    Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:6-13.
    PubMed     Abstract available


  599. SULLIVAN DR, Eden KB, Dieckmann NF, Golden SE, et al
    Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
    Lung Cancer. 2019;131:47-57.
    PubMed     Abstract available


  600. WILLEN L, Berglund A, Bergstrom S, Bergqvist M, et al
    Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.
    Lung Cancer. 2019;131:40-46.
    PubMed     Abstract available


  601. VAYR F, Savall F, Bigay-Game L, Soulat JM, et al
    Lung cancer survivors and employment: A systematic review.
    Lung Cancer. 2019;131:31-39.
    PubMed     Abstract available


  602. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
    Lung Cancer. 2019;131:23-30.
    PubMed     Abstract available


  603. YAN SX, Qureshi MM, Dyer M, Truong MT, et al
    Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Lung Cancer. 2019;131:147-153.
    PubMed     Abstract available


  604. YIN K, Li YS, Zheng MM, Jiang BY, et al
    A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Lung Cancer. 2019;131:134-138.
    PubMed     Abstract available


  605. LATTUCA-TRUC M, Timsit JF, Levra MG, Ruckly S, et al
    Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
    Lung Cancer. 2019;131:122-127.
    PubMed     Abstract available


  606. YAMADA T, Ohta K, Motooka Y, Fujino K, et al
    Significance of Tsukushi in lung cancer.
    Lung Cancer. 2019;131:104-111.
    PubMed     Abstract available


  607. CHRISTENSEN NL, Dalton S, Ravn J, Christensen J, et al
    Treatment, no treatment and early death in Danish stage I lung cancer patients.
    Lung Cancer. 2019;131:1-5.
    PubMed     Abstract available


  608. GAN CT, Verschuuren E, van de Bij W, Van De Wauwer C, et al
    Comment on: Synchronous multiple non-small cell lung cancers in an allograft lung recipient.
    Lung Cancer. 2019;131:154.
    PubMed    


  609. PUJOL JL, Bommart S, Pujol P
    Response to comment on: 'Synchronous multiple non-small cell lung cancers in an allograft lung recipient'.
    Lung Cancer. 2019;131:155-156.
    PubMed    


    April 2019
  610. LAN S, Li H, Liu Y, Ma L, et al
    Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
    Lung Cancer. 2019 Apr 28. pii: S0169-5002(19)30426.
    PubMed    


  611. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].
    Lung Cancer. 2019 Apr 25. pii: S0169-5002(19)30398.
    PubMed    


  612. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
    Lung Cancer. 2019 Apr 24. pii: S0169-5002(19)30399.
    PubMed    


  613. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lu
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30397.
    PubMed    


  614. HARRIS EJA, Musk AW, DeKlerk N, Brims FJH, et al
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30417.
    PubMed    


  615. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Lung Cancer. 2019;130:93-100.
    PubMed     Abstract available


  616. LEE K, Kim Y, Jung HA, Lee SH, et al
    Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
    Lung Cancer. 2019;130:87-92.
    PubMed     Abstract available


  617. JIANG T, Bai Y, Zhou F, Li W, et al
    Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Lung Cancer. 2019;130:76-83.
    PubMed     Abstract available


  618. ARRIETA O, Barron F, Maldonado F, Cabrera L, et al
    Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Lung Cancer. 2019;130:67-75.
    PubMed     Abstract available


  619. GUBENS MA, Sequist LV, Stevenson JP, Powell SF, et al
    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Lung Cancer. 2019;130:59-66.
    PubMed     Abstract available


  620. LA FLEUR L, Falk-Sorqvist E, Smeds P, Berglund A, et al
    Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    Lung Cancer. 2019;130:50-58.
    PubMed     Abstract available


  621. YONESHIMA Y, Tanaka K, Shiraishi Y, Hata K, et al
    Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Lung Cancer. 2019;130:5-9.
    PubMed     Abstract available


  622. PERUMAL E, So Youn K, Sun S, Seung-Hyun J, et al
    PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells.
    Lung Cancer. 2019;130:25-34.
    PubMed     Abstract available


  623. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Lung Cancer. 2019;130:216-225.
    PubMed     Abstract available


  624. LUO Q, Steinberg J, O'Connell DL, Yu XQ, et al
    Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
    Lung Cancer. 2019;130:208-215.
    PubMed     Abstract available


  625. WU YL, Zhou C, Lu S, Qin S, et al
    Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
    Lung Cancer. 2019;130:18-24.
    PubMed     Abstract available


  626. CARNEIRO-LOBO TC, Scalabrini LC, Magalhaes LDS, Cardeal LB, et al
    IKKbeta targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Lung Cancer. 2019;130:169-178.
    PubMed     Abstract available


  627. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Lung Cancer. 2019;130:162-168.
    PubMed     Abstract available


  628. SAKATA Y, Kawamura K, Ichikado K, Shingu N, et al
    The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Lung Cancer. 2019;130:159-161.
    PubMed     Abstract available


  629. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
    Lung Cancer. 2019;130:143-148.
    PubMed     Abstract available


  630. COSTANTINI A, Fallet V, Corny J, Friard S, et al
    Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2019;130:128-134.
    PubMed     Abstract available


  631. MELTZER LR, Unrod M, Simmons VN, Brandon KO, et al
    Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
    Lung Cancer. 2019;130:121-127.
    PubMed     Abstract available


  632. GEERSE OP, Brandenbarg D, Kerstjens HAM, Berendsen AJ, et al
    The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer.
    Lung Cancer. 2019;130:101-107.
    PubMed     Abstract available


  633. ZHAO S, Gao G, Li W, Li X, et al
    Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Lung Cancer. 2019;130:10-17.
    PubMed     Abstract available


  634. ZHOU K, Zhou J, Huang J, Zhang N, et al
    Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Lung Cancer. 2019;130:1-4.
    PubMed     Abstract available


    March 2019
  635. HU SY, Hsieh MS, Hsu HH, Tsai TM, et al
    Corrigendum to "Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas" [Lung Cancer 126 (2018) 189-193].
    Lung Cancer. 2019 Mar 13. pii: S0169-5002(19)30349.
    PubMed    


  636. ONO A, Isaka M, Serizawa M, Omae K, et al
    Corrigendum to "Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer" [Lung Cancer 128 (2019) 152-157].
    Lung Cancer. 2019 Mar 12. pii: S0169-5002(19)30350.
    PubMed    


  637. BRAVACCINI S
    What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Lung Cancer. 2019 Mar 11. pii: S0169-5002(19)30355.
    PubMed     Abstract available


  638. UBERALL I, Gachechiladze M, Joerger M, Andel J, et al
    Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;129:85-91.
    PubMed     Abstract available


  639. MENDOZA DP, Dagogo-Jack I, Chen T, Padole A, et al
    Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.
    Lung Cancer. 2019;129:80-84.
    PubMed     Abstract available


  640. HEILBRONER SP, Xanthopoulos EP, Buono D, Huang Y, et al
    Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer.
    Lung Cancer. 2019;129:8-15.
    PubMed     Abstract available


  641. TUNALI I, Gray JE, Qi J, Abdalah M, et al
    Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Lung Cancer. 2019;129:75-79.
    PubMed     Abstract available


  642. ZHENG X, Zhang G, Li P, Zhang M, et al
    Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Lung Cancer. 2019;129:72-74.
    PubMed     Abstract available


  643. ANDRATSCHKE N, Kraft J, Nieder C, Tay R, et al
    Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;129:63-71.
    PubMed     Abstract available


  644. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Lung Cancer. 2019;129:55-62.
    PubMed     Abstract available


  645. KOH YW, Lee SJ, Han JH, Haam S, et al
    PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
    Lung Cancer. 2019;129:41-47.
    PubMed     Abstract available


  646. CRINO L, Bronte G, Bidoli P, Cravero P, et al
    Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;129:35-40.
    PubMed     Abstract available


  647. GEMINE RE, Ghosal R, Collier G, Parry D, et al
    Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
    Lung Cancer. 2019;129:1-7.
    PubMed     Abstract available


  648. LIU Y, Liu T, Li N, Wang T, et al
    Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Lung Cancer. 2019;129:92-94.
    PubMed     Abstract available


  649. BO L, Li C, Pan L, Wang H, et al
    Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study.
    Lung Cancer. 2019;129:48-54.
    PubMed     Abstract available


  650. YANG B, Lee H, Um SW, Kim K, et al
    Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
    Lung Cancer. 2019;129:28-34.
    PubMed     Abstract available


  651. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Hospital lung surgery volume and patient outcomes.
    Lung Cancer. 2019;129:22-27.
    PubMed     Abstract available


  652. ISHIDA H, Shimizu Y, Sakaguchi H, Nitanda H, et al
    Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
    Lung Cancer. 2019;129:16-21.
    PubMed     Abstract available


  653. YAMASAKI M, Takenaka T, Matsumoto N, Asaoku H, et al
    Primary pulmonary collision tumor comprising squamous cell carcinoma and mucosa-associated lymphoid tissue lymphoma.
    Lung Cancer. 2019;129:107-109.
    PubMed    


    February 2019
  654. SHI JF, Wang L, Wu N, Li JL, et al
    Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey.
    Lung Cancer. 2019;128:91-100.
    PubMed     Abstract available


  655. HORN L, Bauml J, Forde PM, Davis KL, et al
    Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Lung Cancer. 2019;128:74-90.
    PubMed     Abstract available


  656. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
    Lung Cancer. 2019;128:67-73.
    PubMed     Abstract available


  657. YAN X, Wang H, Li P, Zhang G, et al
    Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Lung Cancer. 2019;128:6-12.
    PubMed     Abstract available


  658. NIEUWENHUIS L, van den Brandt PA
    Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study.
    Lung Cancer. 2019;128:57-66.
    PubMed     Abstract available


  659. HAMADA K, Irie M, Fujino Y, Hyodo M, et al
    Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.
    Lung Cancer. 2019;128:47-52.
    PubMed     Abstract available


  660. ZAMARRON E, Prats E, Tejero E, Pardo P, et al
    Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease.
    Lung Cancer. 2019;128:40-46.
    PubMed     Abstract available


  661. MIZUGAKI H, Hamada A, Shibata T, Hosoda F, et al
    Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Lung Cancer. 2019;128:20-25.
    PubMed     Abstract available


  662. SCHUCHERT MJ, Normolle DP, Awais O, Pennathur A, et al
    Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.
    Lung Cancer. 2019;128:145-151.
    PubMed     Abstract available


  663. CEDILLO JL, Bordas A, Arnalich F, Esteban-Rodriguez I, et al
    Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression.
    Lung Cancer. 2019;128:134-144.
    PubMed     Abstract available


  664. ABEL S, Hasan S, White R, Schumacher L, et al
    Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2019;128:127-133.
    PubMed     Abstract available


  665. KOO HJ, Choi CM, Park S, Lee HN, et al
    Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea.
    Lung Cancer. 2019;128:120-126.
    PubMed     Abstract available


  666. ITO K, Miura S, Sakaguchi T, Murotani K, et al
    The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Lung Cancer. 2019;128:113-119.
    PubMed     Abstract available


  667. GADGEEL SM, Lukas RV, Goldschmidt J, Conkling P, et al
    Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
    Lung Cancer. 2019;128:105-112.
    PubMed     Abstract available


  668. STEVENS C, Smith SG, Quaife SL, Vrinten C, et al
    Interest in lifestyle advice at lung cancer screening: Determinants and preferences.
    Lung Cancer. 2019;128:1-5.
    PubMed     Abstract available


  669. MAUCLET C, Duplaquet F, Pirard L, Rondelet B, et al
    Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab.
    Lung Cancer. 2019;128:53-56.
    PubMed     Abstract available


  670. ZHAO S, Li X, Zhao C, Jiang T, et al
    Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Lung Cancer. 2019;128:33-39.
    PubMed     Abstract available


  671. TAKADA K, Kohashi K, Shimokawa M, Haro A, et al
    Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Lung Cancer. 2019;128:26-32.
    PubMed     Abstract available


    January 2019
  672. HENDRIKS LEL, Dingemans AC
    Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
    Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297.
    PubMed    


  673. AULIAC JB, Perol M, Planchard D, Monnet I, et al
    Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Lung Cancer. 2019;127:96-102.
    PubMed     Abstract available


  674. YOON HS, Wen W, Long J, Zheng W, et al
    Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
    Lung Cancer. 2019;127:90-95.
    PubMed     Abstract available


  675. GU X, Zhang Q, Chu YB, Zhao YY, et al
    Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lung Cancer. 2019;127:84-89.
    PubMed     Abstract available


  676. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:76-83.
    PubMed     Abstract available


  677. DOTSON T, Bellinger C, Su J, Hansen K, et al
    Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).
    Lung Cancer. 2019;127:6-11.
    PubMed     Abstract available


  678. SAKAI H, Takeda M, Sakai K, Nakamura Y, et al
    Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Lung Cancer. 2019;127:59-65.
    PubMed     Abstract available


  679. COUTINHO AD, Shah M, Lunacsek OE, Eaddy M, et al
    Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
    Lung Cancer. 2019;127:53-58.
    PubMed     Abstract available


  680. CHOUAID C, Bensimon L, Clay E, Millier A, et al
    Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Lung Cancer. 2019;127:44-52.
    PubMed     Abstract available


  681. THOMPSON JC, Fan R, Black T, Yu GH, et al
    Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Lung Cancer. 2019;127:25-33.
    PubMed     Abstract available


  682. YU Y, Ou Q, Wu X, Bao H, et al
    Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2019;127:19-24.
    PubMed     Abstract available


  683. HASEGAWA H, Yasuda H, Hamamoto J, Masuzawa K, et al
    Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Lung Cancer. 2019;127:146-152.
    PubMed     Abstract available


  684. MONSALVE AF, Hoag JR, Resio BJ, Chiu AS, et al
    Variable impact of prior cancer history on the survival of lung cancer patients.
    Lung Cancer. 2019;127:130-137.
    PubMed     Abstract available


  685. MURAWSKI M, Walter J, Schwarzkopf L
    Assessing the lung cancer comorbidome: An analysis of German claims data.
    Lung Cancer. 2019;127:122-129.
    PubMed     Abstract available


  686. PYO KH, Kim JH, Lee JM, Kim SE, et al
    Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Lung Cancer. 2019;127:112-121.
    PubMed     Abstract available


  687. WU YL, Zhao Q, Deng L, Zhang Y, et al
    Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:1-5.
    PubMed     Abstract available


  688. SUH CH, Kim KW, Nishino M
    Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis i
    Lung Cancer. 2019;127:168.
    PubMed    


  689. CHAPEL DB, Churg A, Santoni-Rugiu E, Tsujimura T, et al
    Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
    Lung Cancer. 2019;127:69-75.
    PubMed     Abstract available


  690. PARK S, Han J, Sun JM
    Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.
    Lung Cancer. 2019;127:66-68.
    PubMed     Abstract available


  691. HSU KH, Huang YH, Tseng JS, Chen KC, et al
    High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients.
    Lung Cancer. 2019;127:37-43.
    PubMed     Abstract available


  692. ROMESSER PB, Bardash Y, Buonocore D, Chaft JE, et al
    Outcomes of Stage III NSCLC with occult primary vs. known primary lesions.
    Lung Cancer. 2019;127:34-36.
    PubMed     Abstract available


  693. MAZZASCHI G, Facchinetti F, Missale G, Canetti D, et al
    The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Lung Cancer. 2019;127:153-163.
    PubMed     Abstract available


  694. WU L, Dell'Anno I, Lapidot M, Sekido Y, et al
    Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
    Lung Cancer. 2019;127:138-145.
    PubMed     Abstract available


  695. ROCA E, Pozzari M, Vermi W, Tovazzi V, et al
    Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
    Lung Cancer. 2019;127:12-18.
    PubMed     Abstract available


  696. HALMOS B, Tan EH, Soo RA, Cadranel J, et al
    Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
    Lung Cancer. 2019;127:103-111.
    PubMed     Abstract available


    December 2018
  697. LIN YT, Chu CY
    Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
    Lung Cancer. 2018 Dec 31. pii: S0169-5002(18)30730.
    PubMed    


  698. ONO A, Isaka M, Serizawa M, Omae K, et al
    Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Lung Cancer. 2018 Dec 5. pii: S0169-5002(18)30691.
    PubMed     Abstract available


  699. CAPIZZI E, Ricci C, Giunchi F, Zagnoni S, et al
    Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Lung Cancer. 2018;126:9-14.
    PubMed     Abstract available


  700. UNG MH, MacKenzie TA, Onega TL, Amos CI, et al
    Statins associate with improved mortality among patients with certain histological subtypes of lung cancer.
    Lung Cancer. 2018;126:89-96.
    PubMed     Abstract available


  701. KOGA T, Kobayashi Y, Tomizawa K, Suda K, et al
    Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Lung Cancer. 2018;126:72-79.
    PubMed     Abstract available


  702. MOREL H, Raynard B, d'Arlhac M, Hauss PA, et al
    Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.
    Lung Cancer. 2018;126:55-63.
    PubMed     Abstract available


  703. HASHEMI SADRAEI N, Feng Y, Du L, Fu P, et al
    High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
    Lung Cancer. 2018;126:48-54.
    PubMed     Abstract available


  704. IMAI H, Kaira K, Suzuki K, Anzai M, et al
    A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2018;126:41-47.
    PubMed     Abstract available


  705. MEIJER TWH, Peeters WJM, Dubois LJ, van Gisbergen MW, et al
    Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
    Lung Cancer. 2018;126:32-40.
    PubMed     Abstract available


  706. UDAGAWA H, Umemura S, Murakami I, Mimaki S, et al
    Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Lung Cancer. 2018;126:182-188.
    PubMed     Abstract available


  707. SCHWYZER M, Ferraro DA, Muehlematter UJ, Curioni-Fontecedro A, et al
    Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks - Initial results.
    Lung Cancer. 2018;126:170-173.
    PubMed     Abstract available


  708. ANAI S, Iwama E, Yoneshima Y, Otsubo K, et al
    Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Lung Cancer. 2018;126:156-161.
    PubMed     Abstract available


  709. JOHN T, Akamatsu H, Delmonte A, Su WC, et al
    EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    Lung Cancer. 2018;126:133-138.
    PubMed     Abstract available


  710. QUIST M, Sommer MS, Vibe-Petersen J, Staerkind MB, et al
    Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial.
    Lung Cancer. 2018;126:125-132.
    PubMed     Abstract available


  711. HINDE S, Crilly T, Balata H, Bartlett R, et al
    The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot.
    Lung Cancer. 2018;126:119-124.
    PubMed     Abstract available


  712. NG TL, Morgan RL, Patil T, Baron AE, et al
    Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
    Lung Cancer. 2018;126:112-118.
    PubMed     Abstract available


    November 2018
  713. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
    Lung Cancer. 2018 Nov 17. pii: S0169-5002(18)30635.
    PubMed    


  714. TANAKA I, Morise M, Kodama Y, Matsui A, et al
    Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
    Lung Cancer. 2018 Nov 14. pii: S0169-5002(18)30645.
    PubMed    


  715. SUN Z, Sui X, Yang F, Wang J, et al
    Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study.
    Lung Cancer. 2018 Nov 13. pii: S0169-5002(18)30639.
    PubMed     Abstract available


  716. ZHAO B, Zhang W
    Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Nov 12. pii: S0169-5002(18)30638.
    PubMed    


  717. HANIBUCHI M, Kakiuchi S, Atagi S, Ogushi F, et al
    A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2018;125:93-99.
    PubMed     Abstract available


  718. LIU SY, Dong ZY, Wu SP, Xie Z, et al
    Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Lung Cancer. 2018;125:86-92.
    PubMed     Abstract available


  719. CHEN K, Yu X, Zhang F, Xu Y, et al
    Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Lung Cancer. 2018;125:8-13.
    PubMed     Abstract available


  720. COSTA GJ, de Mello MJG, Ferreira CG, Bergmann A, et al
    Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.
    Lung Cancer. 2018;125:77-85.
    PubMed     Abstract available


  721. LUO Q, Yu XQ, Wade S, Caruana M, et al
    Lung cancer mortality in Australia: Projected outcomes to 2040.
    Lung Cancer. 2018;125:68-76.
    PubMed     Abstract available


  722. CHECK DK, Albers KB, Uppal KM, Suga JM, et al
    Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members.
    Lung Cancer. 2018;125:51-56.
    PubMed     Abstract available


  723. SOTIROPOULOS GP, Dalamaga M, Antonakos G, Marinou I, et al
    Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
    Lung Cancer. 2018;125:291-299.
    PubMed     Abstract available


  724. BALATA H, Foden P, Edwards T, Chaturvedi A, et al
    Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
    Lung Cancer. 2018;125:29-34.
    PubMed     Abstract available


  725. LIN MW, Su KY, Su TJ, Chang CC, et al
    Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lung Cancer. 2018;125:282-290.
    PubMed     Abstract available


  726. GADGEEL SM, Stevenson JP, Langer CJ, Gandhi L, et al
    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Lung Cancer. 2018;125:273-281.
    PubMed     Abstract available


  727. ISOBE K, Kaburaki K, Kobayashi H, Sano G, et al
    New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia.
    Lung Cancer. 2018;125:253-257.
    PubMed     Abstract available


  728. WANG S, Zhang B, Qian J, Qiao R, et al
    Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Lung Cancer. 2018;125:245-252.
    PubMed     Abstract available


  729. JEGOU D, Dubois C, Schillemans V, Stordeur S, et al
    Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.
    Lung Cancer. 2018;125:238-244.
    PubMed     Abstract available


  730. SAITO T, Tsuta K, Ishida M, Ryota H, et al
    Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
    Lung Cancer. 2018;125:230-237.
    PubMed     Abstract available


  731. KORT S, Tiggeloven MM, Brusse-Keizer M, Gerritsen JW, et al
    Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis.
    Lung Cancer. 2018;125:223-229.
    PubMed     Abstract available


  732. JIA Y, Li X, Zhao C, Jiang T, et al
    Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;125:22-28.
    PubMed     Abstract available


  733. YAMAGUCHI T, Shimizu J, Hasegawa T, Horio Y, et al
    Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Lung Cancer. 2018;125:212-217.
    PubMed     Abstract available


  734. MALHOTRA J, Rotter D, Jabbour SK, Aisner J, et al
    Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.
    Lung Cancer. 2018;125:205-211.
    PubMed     Abstract available


  735. YUTAKA Y, Sonobe M, Kawaguchi A, Hamaji M, et al
    Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.
    Lung Cancer. 2018;125:192-197.
    PubMed     Abstract available


  736. KARLSSON T, Kvarnbrink S, Holmlund C, Botling J, et al
    LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
    Lung Cancer. 2018;125:174-184.
    PubMed     Abstract available


  737. FROST N, Tessmer A, Schmittel A, van Laak V, et al
    Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Lung Cancer. 2018;125:164-173.
    PubMed     Abstract available


  738. DJUREINOVIC D, Dodig-Crnkovic T, Hellstrom C, Holgersson G, et al
    Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Lung Cancer. 2018;125:157-163.
    PubMed     Abstract available


  739. CHO JY, Kim J, Lee JS, Kim YJ, et al
    Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Lung Cancer. 2018;125:150-156.
    PubMed     Abstract available


  740. KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
    Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2018;125:136-141.
    PubMed     Abstract available


  741. DEJIMA H, Nakanishi H, Kuroda H, Yoshimura M, et al
    Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.
    Lung Cancer. 2018;125:128-135.
    PubMed     Abstract available


  742. MOFFAT J, Hiom S, Kumar HS, Baldwin DR, et al
    Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK.
    Lung Cancer. 2018;125:121-127.
    PubMed     Abstract available


  743. REN S, Tian Q, Amar N, Yu H, et al
    The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Lung Cancer. 2018;125:115-120.
    PubMed     Abstract available


  744. WALTER JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, et al
    Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.
    Lung Cancer. 2018;125:103-108.
    PubMed     Abstract available


  745. EZEIFE DA, Kirk V, Chew DS, Nixon NA, et al
    Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Lung Cancer. 2018;125:1-7.
    PubMed     Abstract available


    October 2018
  746. LUCCHESI C, Drogat B, Santamaria D, Cousin S, et al
    Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lung Cancer. 2018 Oct 12. pii: S0169-5002(18)30597.
    PubMed    


  747. ILIE M, Beaulande M, Hamila M, Erb G, et al
    Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Lung Cancer. 2018;124:90-94.
    PubMed     Abstract available


  748. HARRIS JP, Nwachukwu C, Qian Y, Pollom E, et al
    Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
    Lung Cancer. 2018;124:76-85.
    PubMed     Abstract available


  749. UCHIBORI K, Satouchi M, Sueoka-Aragane N, Urata Y, et al
    Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Lung Cancer. 2018;124:65-70.
    PubMed     Abstract available


  750. DE JONG EEC, van Elmpt W, Rizzo S, Colarieti A, et al
    Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    Lung Cancer. 2018;124:6-11.
    PubMed     Abstract available


  751. FERRER I, Zugazagoitia J, Herbertz S, John W, et al
    KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Lung Cancer. 2018;124:53-64.
    PubMed     Abstract available


  752. CHRISTENSEN NL, Lokke A, Dalton SO, Christensen J, et al
    Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients.
    Lung Cancer. 2018;124:40-44.
    PubMed     Abstract available


  753. BIRCAN HA, Gurbuz N, Pataer A, Caner A, et al
    Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
    Lung Cancer. 2018;124:31-39.
    PubMed     Abstract available


  754. LIM SW, Park S, Kim Y, Cho JH, et al
    Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lung Cancer. 2018;124:293-297.
    PubMed     Abstract available


  755. HASAN S, Renz P, Turrisi A, Colonias A, et al
    Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
    Lung Cancer. 2018;124:283-290.
    PubMed     Abstract available


  756. MESSARITAKIS I, Nikolaou M, Politaki E, Koinis F, et al
    Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Lung Cancer. 2018;124:270-278.
    PubMed     Abstract available


  757. OKAMOTO T, Yano T, Shimokawa M, Takeo S, et al
    A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
    Lung Cancer. 2018;124:255-259.
    PubMed     Abstract available


  758. GEORGIEVA M, da Silveira Nogueira Lima JP, Aguiar P Jr, de Lima Lopes G Jr, et al
    Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;124:248-254.
    PubMed     Abstract available


  759. HASHIMOTO T, Osoegawa A, Takumi Y, Abe M, et al
    Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
    Lung Cancer. 2018;124:241-247.
    PubMed     Abstract available


  760. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2018;124:233-240.
    PubMed     Abstract available


  761. NAJJAR F, Alammar M, Al-Massarani G, Almalla N, et al
    Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer.
    Lung Cancer. 2018;124:23-30.
    PubMed     Abstract available


  762. HSIEH MS, Lee YH, Lin MW, Chen JS, et al
    Solitary pulmonary capillary hemangioma: An under-recognized pulmonary lesion mimicking early lung cancer on computed tomography images.
    Lung Cancer. 2018;124:227-232.
    PubMed     Abstract available


  763. MERINO LARA T, Helou J, Poon I, Sahgal A, et al
    Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Lung Cancer. 2018;124:219-226.
    PubMed     Abstract available


  764. STONE E, Rankin N, Kerr S, Fong K, et al
    Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study.
    Lung Cancer. 2018;124:199-204.
    PubMed     Abstract available


  765. HOFER F, Kauczor HU, Stargardt T
    Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
    Lung Cancer. 2018;124:189-198.
    PubMed     Abstract available


  766. SEKINE K, Kanda S, Goto Y, Horinouchi H, et al
    Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Lung Cancer. 2018;124:179-188.
    PubMed     Abstract available


  767. KANG HN, Choi JW, Shim HS, Kim J, et al
    Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Lung Cancer. 2018;124:168-178.
    PubMed     Abstract available


  768. CLARK ME, Bedford LE, Young B, Robertson JFR, et al
    Lung cancer CT screening: Psychological responses in the presence and absence of pulmonary nodules.
    Lung Cancer. 2018;124:160-167.
    PubMed     Abstract available


  769. SIM WC, Loh CH, Toh GL, Lim CW, et al
    Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Lung Cancer. 2018;124:154-159.
    PubMed     Abstract available


  770. BALATA H, Blandin Knight S, Barber P, Colligan D, et al
    Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.
    Lung Cancer. 2018;124:148-153.
    PubMed     Abstract available


  771. LAFITTE C, Etienne-Mastroianni B, Fournel C, Natoli L, et al
    Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer.
    Lung Cancer. 2018;124:143-147.
    PubMed     Abstract available


  772. YAN SX, Qureshi MM, Suzuki K, Dyer M, et al
    Definitive treatment patterns and survival in stage II non-small cell lung cancer.
    Lung Cancer. 2018;124:135-142.
    PubMed     Abstract available


  773. DUDNIK E, Bshara E, Grubstein A, Fridel L, et al
    Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
    Lung Cancer. 2018;124:117-124.
    PubMed     Abstract available


  774. GRANGER CL, Irving L, Antippa P, Edbrooke L, et al
    CAPACITY: A physical activity self-management program for patients undergoing surgery for lung cancer, a phase I feasibility study.
    Lung Cancer. 2018;124:102-109.
    PubMed     Abstract available


  775. MATYS T, Drury R, David S, Rassl DM, et al
    Corrigendum to "Routine preoperative brain CT in resectable non-small cell lung cancer-Ten years experience from a tertiary UK thoracic center" [Lung Cancer 122 (August) (2018) 195-199].
    Lung Cancer. 2018 Oct 1. pii: S0169-5002(18)30575.
    PubMed    


    September 2018
  776. XU R, Zhu J
    Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018 Sep 24. pii: S0169-5002(18)30577.
    PubMed    


  777. XU R, Zhu J
    Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Sep 7. pii: S0169-5002(18)30559.
    PubMed    


  778. GARON EB, Siegfried JM, Stabile LP, Young PA, et al
    Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
    Lung Cancer. 2018;123:91-98.
    PubMed     Abstract available


  779. SCILLA KA, Zandberg DP, Bentzen SM, Mainor C, et al
    Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Lung Cancer. 2018;123:87-90.
    PubMed     Abstract available


  780. VUONG HG, Ho ATN, Altibi AMA, Nakazawa T, et al
    Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Lung Cancer. 2018;123:76-82.
    PubMed     Abstract available


  781. JIAO XD, Qin BD, You P, Cai J, et al
    The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Lung Cancer. 2018;123:70-75.
    PubMed     Abstract available


  782. SONG Y, Zhou Q, Zhang X, Chen GY, et al
    Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
    Lung Cancer. 2018;123:7-13.
    PubMed     Abstract available


  783. SUH CH, Park HS, Kim KW, Pyo J, et al
    Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018;123:60-69.
    PubMed     Abstract available


  784. LU S, Kong H, Hou Y, Ge D, et al
    Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
    Lung Cancer. 2018;123:44-51.
    PubMed     Abstract available


  785. LIU F, Liu Y, Liu X, Mao K, et al
    Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Lung Cancer. 2018;123:36-43.
    PubMed     Abstract available


  786. TAIRA N, Atsumi E, Nakachi S, Takamatsu R, et al
    Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
    Lung Cancer. 2018;123:30-35.
    PubMed     Abstract available


  787. JAO K, Tomasini P, Kamel-Reid S, Korpanty GJ, et al
    The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Lung Cancer. 2018;123:22-29.
    PubMed     Abstract available


  788. HU X, Hay JW
    First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Lung Cancer. 2018;123:166-171.
    PubMed     Abstract available


  789. STEWART I, Khakwani A, Hubbard RB, Beckett P, et al
    Are working practices of lung cancer nurse specialists associated with variation in peoples' receipt of anticancer therapy?
    Lung Cancer. 2018;123:160-165.
    PubMed     Abstract available


  790. CARDINALE D, Cosentino N, Moltrasio M, Sandri MT, et al
    Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide.
    Lung Cancer. 2018;123:155-159.
    PubMed     Abstract available


  791. POMPILI C, Koller M, Velikova G, Franks K, et al
    EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
    Lung Cancer. 2018;123:149-154.
    PubMed     Abstract available


  792. CHO BC, Dy GK, Govindan R, Kim DW, et al
    Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    Lung Cancer. 2018;123:14-21.
    PubMed     Abstract available


  793. FINKLE JH, Penney BC, Pu Y
    An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Lung Cancer. 2018;123:136-141.
    PubMed     Abstract available


  794. LI Z, Maeda D, Yoshida M, Umakoshi M, et al
    The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Lung Cancer. 2018;123:127-135.
    PubMed     Abstract available


  795. KOUL R, Rathod S, Dubey A, Bashir B, et al
    Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Lung Cancer. 2018;123:116-120.
    PubMed     Abstract available


  796. DE JONG EEC, Hendriks LEL, van Elmpt W, Gietema HA, et al
    What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.
    Lung Cancer. 2018;123:112-115.
    PubMed     Abstract available


  797. HASHIMOTO K, Daddi N, Giuliani M, Hope A, et al
    The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
    Lung Cancer. 2018;123:1-6.
    PubMed     Abstract available


    August 2018
  798. DICKHOFF C, Dahele M
    In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
    PubMed    


  799. CHOUAID C, Danson S, Andreas S, Siakpere O, et al
    Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
    Lung Cancer. 2018 Aug 10. pii: S0169-5002(18)30503.
    PubMed     Abstract available


  800. LEE YG, Lee JH, Kim SH, Kim YJ, et al
    Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
    Lung Cancer. 2018;122:88-93.
    PubMed     Abstract available


  801. HO JC, Leung CC
    Management of co-existent tuberculosis and lung cancer.
    Lung Cancer. 2018;122:83-87.
    PubMed     Abstract available


  802. GUIBERT N, Tsukada H, Hwang DH, Chambers E, et al
    Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
    Lung Cancer. 2018;122:72-75.
    PubMed     Abstract available


  803. CHAFT JE, Dagogo-Jack I, Santini FC, Eng J, et al
    Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Lung Cancer. 2018;122:67-71.
    PubMed     Abstract available


  804. DENG W, Xu T, Wang Y, Xu Y, et al
    Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
    Lung Cancer. 2018;122:60-66.
    PubMed     Abstract available


  805. OSUOHA CA, Callahan KE, Ponce CP, Pinheiro PS, et al
    Disparities in lung cancer survival and receipt of surgical treatment.
    Lung Cancer. 2018;122:54-59.
    PubMed     Abstract available


  806. SI X, Zhang L, Wang H, Zhang X, et al
    Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:32-37.
    PubMed     Abstract available


  807. TRIPHURIDET N, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, et al
    Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Lung Cancer. 2018;122:243-248.
    PubMed     Abstract available


  808. LEE JS, Lee KH, Cho EK, Kim DW, et al
    Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lung Cancer. 2018;122:234-242.
    PubMed     Abstract available


  809. ZAHEDI A, Phandthong R, Chaili A, Remark G, et al
    Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.
    Lung Cancer. 2018;122:224-233.
    PubMed     Abstract available


  810. AHMED T, Vial MR, Ost D, Stewart J, et al
    Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
    Lung Cancer. 2018;122:220-223.
    PubMed     Abstract available


  811. TAKAHASHI N, Tsuji K, Tamiya H, Shinohara T, et al
    Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
    Lung Cancer. 2018;122:22-24.
    PubMed     Abstract available


  812. GOYAL G, Kommalapati A, Bartley AC, Gunderson TM, et al
    Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
    Lung Cancer. 2018;122:214-219.
    PubMed     Abstract available


  813. ROBINSON LA, Tanvetyanon T, Grubbs D, Antonia S, et al
    Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018;122:206-213.
    PubMed     Abstract available


  814. IZUMI H, Yamasaki A, Takeda K, Kodani M, et al
    Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:200-205.
    PubMed     Abstract available


  815. MATYS T, Drury R, David S, Rassl DM, et al
    Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
    Lung Cancer. 2018;122:195-199.
    PubMed     Abstract available


  816. YAP S, Goldsbury D, Yap ML, Yuill S, et al
    Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.
    Lung Cancer. 2018;122:171-179.
    PubMed     Abstract available


  817. BRUSTUGUN OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, et al
    Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
    Lung Cancer. 2018;122:138-145.
    PubMed     Abstract available


  818. MILLARES L, Barreiro E, Cortes R, Martinez-Romero A, et al
    Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
    Lung Cancer. 2018;122:124-130.
    PubMed     Abstract available


  819. INOUE T, Katoh N, Ito YM, Kimura T, et al
    Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study.
    Lung Cancer. 2018;122:107-112.
    PubMed     Abstract available


  820. SEBASTIAN M, Ryden A, Walding A, Papadimitrakopoulou V, et al
    Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:100-106.
    PubMed     Abstract available


  821. ZHAO B, Zhang W, Yu D, Xu J, et al
    Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018;122:10-21.
    PubMed     Abstract available


  822. WANG H, Zhang L, Hu P, Zheng X, et al
    Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
    Lung Cancer. 2018;122:1-6.
    PubMed     Abstract available


    July 2018
  823. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].
    Lung Cancer. 2018 Jul 13. pii: S0169-5002(18)30468.
    PubMed    


  824. VERONESI G, Zulueta JJ, Maisonneuve P, Henschke C, et al
    At last we can go ahead with low-dose CT screening for lung cancer in Europe.
    Lung Cancer. 2018 Jul 10. pii: S0169-5002(18)30470.
    PubMed    


  825. KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
    Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Lung Cancer. 2018;121:76-81.
    PubMed     Abstract available


  826. TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
    Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Lung Cancer. 2018;121:61-69.
    PubMed     Abstract available


  827. XIE F, Zhang Y, Mao X, Zheng X, et al
    Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
    Lung Cancer. 2018;121:54-60.
    PubMed     Abstract available


  828. NIE K, Zhang Z, Zhang C, Geng C, et al
    Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Lung Cancer. 2018;121:5-11.
    PubMed     Abstract available


  829. KOBAYASHI H, Naito T, Omae K, Omori S, et al
    ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Lung Cancer. 2018;121:48-53.
    PubMed     Abstract available


  830. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2018;121:37-40.
    PubMed     Abstract available


  831. TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
    Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;121:30-36.
    PubMed     Abstract available


  832. YANG M, Tong X, Xu X, Zheng E, et al
    Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
    Lung Cancer. 2018;121:1-4.
    PubMed     Abstract available


    June 2018
  833. ANDREAS S, Chouaid C, Danson S, Siakpere O, et al
    Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416.
    PubMed     Abstract available


  834. KIMURA S, Harada T, Ijichi K, Tanaka K, et al
    Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
    Lung Cancer. 2018;120:98-107.
    PubMed     Abstract available


  835. LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
    Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Lung Cancer. 2018;120:91-97.
    PubMed     Abstract available


  836. ROBIN TP, Jones BL, Amini A, Koshy M, et al
    Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
    Lung Cancer. 2018;120:88-90.
    PubMed     Abstract available


  837. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
    Lung Cancer. 2018;120:75-81.
    PubMed     Abstract available


  838. RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
    Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
    Lung Cancer. 2018;120:62-69.
    PubMed     Abstract available


  839. LEE CC, Zheng H, Soon YY, Foo LL, et al
    Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
    Lung Cancer. 2018;120:54-59.
    PubMed     Abstract available


  840. FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
    A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Lung Cancer. 2018;120:27-33.
    PubMed     Abstract available


  841. BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
    Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Lung Cancer. 2018;120:142-148.
    PubMed     Abstract available


  842. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Lung Cancer. 2018;120:137-141.
    PubMed     Abstract available


  843. DU M, Thompson J, Fisher H, Zhang P, et al
    Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Lung Cancer. 2018;120:113-121.
    PubMed     Abstract available


  844. GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
    PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Lung Cancer. 2018;120:108-112.
    PubMed     Abstract available


  845. REITER MJ, Nemesure A, Madu E, Reagan L, et al
    Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
    Lung Cancer. 2018;120:1-6.
    PubMed     Abstract available


    May 2018
  846. BRAILLON A
    Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
    PubMed    


  847. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
    Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
    PubMed    


  848. D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
    Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
    Lung Cancer. 2018;119:78-84.
    PubMed     Abstract available


  849. RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
    The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
    Lung Cancer. 2018;119:7-13.
    PubMed     Abstract available


  850. YANG SM, Chen LW, Wang HJ, Chen LR, et al
    Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
    Lung Cancer. 2018;119:56-63.
    PubMed     Abstract available


  851. CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
    Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
    Lung Cancer. 2018;119:48-55.
    PubMed     Abstract available


  852. MODING EJ, Diehn M, Wakelee HA
    Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Lung Cancer. 2018;119:42-47.
    PubMed     Abstract available


  853. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Lung Cancer. 2018;119:14-20.
    PubMed     Abstract available


  854. BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
    Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Lung Cancer. 2018;119:112-119.
    PubMed     Abstract available


  855. BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
    Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;119:103-111.
    PubMed     Abstract available


  856. KANG YK, Song YS, Cho S, Jheon S, et al
    Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
    Lung Cancer. 2018;119:1-6.
    PubMed     Abstract available


    April 2018
  857. TSAO MS, Yoon JY
    The eighth TNM classification for lung cancer-What is next?
    Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
    PubMed    


  858. YEN CC, Su HC, Chu CY, Lai SJ, et al
    Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
    PubMed    


  859. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Abstract available


  860. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Abstract available


  861. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Abstract available


  862. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Abstract available


  863. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Abstract available


  864. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Abstract available


  865. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Abstract available


  866. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Abstract available


  867. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Abstract available


  868. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Abstract available


  869. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Abstract available


  870. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Abstract available


    March 2018
  871. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed    


  872. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed    


  873. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Abstract available


  874. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Abstract available


  875. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Abstract available


  876. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Abstract available


  877. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Abstract available


  878. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Abstract available


  879. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Abstract available


  880. PARK BJ, Cho JH, Lee JH, Shin S, et al
    Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
    Lung Cancer. 2018;117:7-13.
    PubMed     Abstract available


    February 2018
  881. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed    


  882. BARUA S, Fang P, Sharma A, Fujimoto J, et al
    Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
    PubMed     Abstract available


  883. VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
    Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    Lung Cancer. 2018;116:90-95.
    PubMed     Abstract available


  884. CHENG CC, Chou KF, Wu CW, Su NW, et al
    EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:80-89.
    PubMed     Abstract available


  885. ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
    A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Lung Cancer. 2018;116:7-14.
    PubMed     Abstract available


  886. GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
    Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Lung Cancer. 2018;116:62-66.
    PubMed     Abstract available


  887. DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;116:55-61.
    PubMed     Abstract available


  888. CUI S, Cheng Z, Qin W, Jiang L, et al
    Exosomes as a liquid biopsy for lung cancer.
    Lung Cancer. 2018;116:46-54.
    PubMed     Abstract available


  889. PARK KS, Moon YW, Raffeld M, Lee DH, et al
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer. 2018;116:38-45.
    PubMed     Abstract available


  890. ARNEY J, Helm A, Crook T, Braun UK, et al
    Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Lung Cancer. 2018;116:25-29.
    PubMed     Abstract available


  891. MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
    ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:15-24.
    PubMed     Abstract available


  892. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
    Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
    PubMed    


  893. PAAJANEN J, Laaksonen S, Ilonen I, Wolff H, et al
    Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Lung Cancer. 2018;116:73-79.
    PubMed     Abstract available


  894. QIN BD, Jiao XD, Zang YS
    Primary pulmonary leiomyosarcoma: A population-based study.
    Lung Cancer. 2018;116:67-72.
    PubMed     Abstract available


  895. ZHOU F, Hou L, Ding T, Song Q, et al
    Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Lung Cancer. 2018;116:30-37.
    PubMed     Abstract available


  896. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
    Lung Cancer. 2018;116:1-6.
    PubMed     Abstract available


  897. CHEN Y, Chen B, Zhu X, Zhong J, et al
    A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Lung Cancer. 2018;116:96-98.
    PubMed    


    January 2018
  898. GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
    Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
    Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
    PubMed    


  899. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Abstract available


  900. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Abstract available


  901. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Abstract available


  902. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Abstract available


  903. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Abstract available


  904. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Abstract available


  905. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Abstract available


  906. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Abstract available


  907. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Abstract available


  908. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Abstract available


  909. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Abstract available


  910. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Abstract available


  911. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Abstract available


  912. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Abstract available


  913. NAKAMURA H, Ichikawa T, Nakasone S, Miyoshi T, et al
    Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Lung Cancer. 2018;115:56-63.
    PubMed     Abstract available


  914. JIANG J, Wu X, Tong X, Wei W, et al
    GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Lung Cancer. 2018;115:5-11.
    PubMed     Abstract available


  915. MIURA Y, Kaira K, Sakurai R, Sunaga N, et al
    High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Lung Cancer. 2018;115:42-48.
    PubMed     Abstract available


  916. MINARI R, Bordi P, Del Re M, Facchinetti F, et al
    Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Lung Cancer. 2018;115:21-27.
    PubMed     Abstract available


  917. GALLI G, Corrao G, Imbimbo M, Proto C, et al
    Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
    Lung Cancer. 2018;115:135-142.
    PubMed     Abstract available


  918. ZHU YC, Wang WX, Xu CW, Song ZB, et al
    EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
    Lung Cancer. 2018;115:131-134.
    PubMed     Abstract available


  919. ZHANG L, Belani CP, Zhang PH, Wang X, et al
    Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.
    Lung Cancer. 2018;115:121-126.
    PubMed     Abstract available


  920. HORNE ZD, Richman AH, Dohopolski MJ, Clump DA, et al
    Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Lung Cancer. 2018;115:1-4.
    PubMed     Abstract available


    December 2017
  921. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed    


  922. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed    


  923. GROSSI F, Genova C, Rijavec E, Barletta G, et al
    Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
    PubMed     Abstract available


  924. TU HY, Ke EE, Yang JJ, Sun YL, et al
    A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;114:96-102.
    PubMed     Abstract available


  925. TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
    Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
    Lung Cancer. 2017;114:90-95.
    PubMed     Abstract available


  926. SHEN J, Ye Y, Chang DW, Huang M, et al
    Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Lung Cancer. 2017;114:70-78.
    PubMed     Abstract available


  927. CHALMERS A, Jensen L, Akerley W
    Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Lung Cancer. 2017;114:68-69.
    PubMed     Abstract available


  928. ZHU Y, Li T, Chen G, Yan G, et al
    Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
    Lung Cancer. 2017;114:6-11.
    PubMed     Abstract available


  929. KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
    Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Lung Cancer. 2017;114:56-61.
    PubMed     Abstract available


  930. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2017;114:44-49.
    PubMed     Abstract available


  931. WANG X, Leader JK, Wang R, Wilson D, et al
    Vasculature surrounding a nodule: A novel lung cancer biomarker.
    Lung Cancer. 2017;114:38-43.
    PubMed     Abstract available


  932. ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
    Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
    Lung Cancer. 2017;114:1-5.
    PubMed     Abstract available


  933. HAN L, Lee CK, Pang H, Chan HT, et al
    Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Lung Cancer. 2017;114:79-89.
    PubMed     Abstract available


  934. YAMAUCHI Y, Safi S, Muley T, Warth A, et al
    C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Lung Cancer. 2017;114:62-67.
    PubMed     Abstract available


  935. KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
    Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
    Lung Cancer. 2017;114:50-55.
    PubMed     Abstract available


  936. WANG L, Guo Q, Yu W, Qiao L, et al
    Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Lung Cancer. 2017;114:31-37.
    PubMed     Abstract available


  937. MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
    Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Lung Cancer. 2017;114:23-30.
    PubMed     Abstract available


  938. FOY V, Schenk MW, Baker K, Gomes F, et al
    Targeting DNA damage in SCLC.
    Lung Cancer. 2017;114:12-22.
    PubMed     Abstract available


    November 2017
  939. DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
    PubMed     Abstract available


  940. SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
    Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
    PubMed    


  941. GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
    Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
    Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
    PubMed    


  942. GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
    Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
    Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
    PubMed    


  943. AHMED Z, Grover P, Kennedy KF, Masood A, et al
    Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
    Lung Cancer. 2017;113:85-87.
    PubMed    


  944. SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
    Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung Cancer. 2017;113:79-84.
    PubMed     Abstract available


  945. KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
    CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Lung Cancer. 2017;113:72-78.
    PubMed     Abstract available


  946. KATO T, Jin CS, Ujiie H, Lee D, et al
    Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
    Lung Cancer. 2017;113:59-68.
    PubMed     Abstract available


  947. HORN L, Gettinger S, Camidge DR, Smit EF, et al
    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer. 2017;113:51-58.
    PubMed     Abstract available


  948. HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
    Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Lung Cancer. 2017;113:45-50.
    PubMed     Abstract available


  949. HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
    Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Lung Cancer. 2017;113:4-6.
    PubMed     Abstract available


  950. CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
    An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
    Lung Cancer. 2017;113:30-36.
    PubMed     Abstract available


  951. LIU C, Cui H, Gu D, Zhang M, et al
    Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
    Lung Cancer. 2017;113:18-29.
    PubMed     Abstract available


  952. BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
    Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
    Lung Cancer. 2017;113:140-151.
    PubMed     Abstract available


  953. SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
    Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Lung Cancer. 2017;113:14-17.
    PubMed     Abstract available


  954. ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
    Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
    Lung Cancer. 2017;113:134-139.
    PubMed     Abstract available


  955. SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
    CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Lung Cancer. 2017;113:121-127.
    PubMed     Abstract available


  956. TALBOT T, Dangoor A, Shah R, Naik J, et al
    The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
    Lung Cancer. 2017;113:115-120.
    PubMed     Abstract available


  957. LEE CK, Kim S, Lee JS, Lee JE, et al
    Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lung Cancer. 2017;113:106-114.
    PubMed     Abstract available


  958. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
    Lung Cancer. 2017;113:1-3.
    PubMed     Abstract available


    October 2017
  959. SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
    PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Lung Cancer. 2017;112:96-101.
    PubMed     Abstract available


  960. SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
    Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:90-95.
    PubMed     Abstract available


  961. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
    Lung Cancer. 2017;112:81-89.
    PubMed     Abstract available


  962. HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
    MHC class II expression in lung cancer.
    Lung Cancer. 2017;112:75-80.
    PubMed     Abstract available


  963. ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
    Serum lipid profile discriminates patients with early lung cancer from healthy controls.
    Lung Cancer. 2017;112:69-74.
    PubMed     Abstract available


  964. FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
    LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Lung Cancer. 2017;112:62-68.
    PubMed     Abstract available


  965. TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
    Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
    Lung Cancer. 2017;112:57-61.
    PubMed     Abstract available


  966. LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
    Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
    Lung Cancer. 2017;112:35-40.
    PubMed     Abstract available


  967. NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
    Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Lung Cancer. 2017;112:25-34.
    PubMed     Abstract available


  968. KUYAMA S, Ochi N, Bessho A, Hotta K, et al
    A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Lung Cancer. 2017;112:188-194.
    PubMed     Abstract available


  969. RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
    Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Lung Cancer. 2017;112:181-187.
    PubMed     Abstract available


  970. QIN N, Wang C, Zhu M, Lu Q, et al
    Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
    Lung Cancer. 2017;112:169-175.
    PubMed     Abstract available


  971. LARA JD, Brunson A, Riess JW, Kelly K, et al
    Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lung Cancer. 2017;112:165-168.
    PubMed     Abstract available


  972. VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
    Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Lung Cancer. 2017;112:16-24.
    PubMed     Abstract available


  973. JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
    Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
    Lung Cancer. 2017;112:156-164.
    PubMed     Abstract available


  974. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
    Lung Cancer. 2017;112:140-155.
    PubMed     Abstract available


  975. KWINT M, Walraven I, Burgers S, Hartemink K, et al
    Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Lung Cancer. 2017;112:134-139.
    PubMed     Abstract available


  976. PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
    Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:126-133.
    PubMed     Abstract available


  977. AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
    Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Lung Cancer. 2017;112:118-125.
    PubMed     Abstract available


  978. SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
    Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
    Lung Cancer. 2017;112:109-117.
    PubMed     Abstract available


  979. MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
    Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
    Lung Cancer. 2017;112:10-15.
    PubMed     Abstract available


    September 2017
  980. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Abstract available


  981. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Abstract available


  982. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Abstract available


  983. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Abstract available


  984. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Abstract available


  985. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Abstract available


  986. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Abstract available


  987. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Abstract available


  988. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Abstract available


  989. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Abstract available


  990. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Abstract available


  991. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Abstract available


  992. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Abstract available


  993. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Abstract available


  994. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Abstract available


  995. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Abstract available


  996. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Abstract available


  997. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Abstract available


  998. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Abstract available


  999. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Abstract available


    August 2017
  1000. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Abstract available


  1001. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed    


  1002. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Abstract available


  1003. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Abstract available


  1004. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Abstract available


  1005. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Abstract available


  1006. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Abstract available


  1007. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Abstract available


  1008. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Abstract available


    July 2017
  1009. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed    


  1010. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Abstract available


  1011. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed    


  1012. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Abstract available


  1013. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Abstract available


  1014. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Abstract available


  1015. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Abstract available


  1016. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Abstract available


  1017. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Abstract available


  1018. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Abstract available


  1019. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Abstract available


  1020. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Abstract available


  1021. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Abstract available


  1022. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Abstract available


  1023. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Abstract available


  1024. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Abstract available


  1025. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Abstract available


  1026. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Abstract available


  1027. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Abstract available


  1028. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Abstract available


  1029. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Abstract available


  1030. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Abstract available


  1031. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Abstract available


  1032. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Abstract available


  1033. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Abstract available


    June 2017
  1034. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed    


  1035. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Abstract available


  1036. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Abstract available


  1037. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Abstract available


  1038. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Abstract available


  1039. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Abstract available


  1040. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Abstract available


  1041. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Abstract available


  1042. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Abstract available


  1043. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Abstract available


  1044. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Abstract available


  1045. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Abstract available


  1046. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Abstract available


  1047. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Abstract available


  1048. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Abstract available


  1049. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Abstract available


  1050. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Abstract available


  1051. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Abstract available


  1052. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Abstract available


  1053. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Abstract available


  1054. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Abstract available


  1055. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Abstract available


  1056. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Abstract available


  1057. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Abstract available


    April 2017
  1058. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed    


  1059. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed    


  1060. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed    


  1061. METRO G, Tazza M, Matocci R, Chiari R, et al
    Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Lung Cancer. 2017;106:58-66.
    PubMed     Abstract available


  1062. BASLER L, Kroeze SG, Guckenberger M
    SBRT for oligoprogressive oncogene addicted NSCLC.
    Lung Cancer. 2017;106:50-57.
    PubMed     Abstract available


  1063. VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
    Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    Lung Cancer. 2017;106:17-21.
    PubMed     Abstract available


  1064. KWON D, Koh J, Kim S, Go H, et al
    MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Lung Cancer. 2017;106:131-137.
    PubMed     Abstract available


  1065. HONG SW, Park NS, Noh MH, Shim JA, et al
    Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Lung Cancer. 2017;106:115-124.
    PubMed     Abstract available


    March 2017
  1066. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Abstract available


  1067. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed    


    February 2017
  1068. HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
    Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Lung Cancer. 2017;104:98-105.
    PubMed     Abstract available


  1069. SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
    Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
    Lung Cancer. 2017;104:70-74.
    PubMed     Abstract available


  1070. TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
    The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Lung Cancer. 2017;104:7-15.
    PubMed     Abstract available


  1071. LAURIE SA, Hao D, Leighl NB, Goffin J, et al
    A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Lung Cancer. 2017;104:65-69.
    PubMed     Abstract available


  1072. WU YL, Saijo N, Thongprasert S, Yang JC, et al
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Lung Cancer. 2017;104:119-125.
    PubMed     Abstract available


    January 2017
  1073. TO KK, Tong WS, Fu LW
    Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    Lung Cancer. 2017;103:58-65.
    PubMed     Abstract available


  1074. TSIM S, Stobo DB, Alexander L, Kelly C, et al
    The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
    Lung Cancer. 2017;103:38-43.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: